Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-10820A |
Brand: | MCE |
CAS: | 150399-23-8 |
MDL | MFCD07779402 |
---|---|
Molecular Weight | 471.37 |
Molecular Formula | C20H19N5Na2O6 |
SMILES | O=C1NC(N)=NC2=C1C(CCC3=CC=C(C=C3)C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)=CN2 |
Pemetrexed disodium (LY231514 disodium) is an antifolate , the K i s of the pentaglutamate of Pemetrexed disodium are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR) , and glycinamide ribonucleotide formyltransferase (GARFT), respectively [1] .
Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT) [1]
Pemetrexed (LY231514) disodium is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites. Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (K m =1.6 μM and V max /K m =621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles in determining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderately inhibits TS (K i =340 nM, recombinant mouse), the pentaglutamate of LY23l5l4 is 100-fold more potent (K i =3.4 nM), making LY231514 one of the most potent folate-based TS inhibitors [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. In a survival analysis, significantly better survival is observed in the group of mice treated with PC61 plus Pemetrexed compare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00109096 | Eli Lilly and Company |
Ovarian Neoplasms|Primary Peritoneal Cancer
|
June 2005 | Phase 2 |
NCT04512430 | Fundación GECP |
Non Small Cell Lung Cancer|EGFR Gene Mutation
|
December 2, 2020 | Phase 2 |
NCT01783197 | Canadian Cancer Trials Group|AstraZeneca |
Non Small Cell Lung Cancer
|
January 30, 2013 | Phase 1 |
NCT01232452 | Eli Lilly and Company |
Non-Small-Cell Lung Carcinoma
|
April 2011 | Phase 2 |
NCT03623776 | Sun Yat-sen University |
Efficacy and Safety
|
February 1, 2019 | Phase 2 |
NCT02322281 | Clovis Oncology, Inc. |
Non-small Cell Lung Cancer
|
February 2015 | Phase 3 |
NCT03793179 | National Cancer Institute (NCI) |
Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
February 28, 2019 | Phase 3 |
NCT04163432 | University of Utah|AstraZeneca |
Non-Small Cell Lung Cancer Metastatic
|
June 16, 2020 | Phase 2 |
NCT00530621 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
September 2007 | Phase 2 |
NCT00489983 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
July 2003 | Phase 2 |
NCT04843007 | NanoAlvand |
Non Small Cell Lung Cancer|Malignant Pleural Mesothelioma
|
October 5, 2016 | |
NCT03380871 | BioNTech US Inc.|Merck Sharp & Dohme LLC|BioNTech SE |
Carcinoma, Non-Small-Cell Lung|Lung Cancer|Nonsquamous Nonsmall Cell Neoplasm of Lung
|
May 4, 2018 | Phase 1 |
NCT02145078 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
June 2014 | Not Applicable |
NCT05305885 | The First Hospital of Jilin University|The Second Hospital of Hebei Medical University|Second Affiliated Hospital of Guangzhou Medical University|The Affiliated Hospital of Guangdong Medical College|Guangdong 999 Brain Hospital|Wuxi People´s Hospital|Huizhou Third People´s Hospital, Guangzhou Medical University|Panjin Liaoyou Gem Flower Hospital |
Leptomeningeal Metastasis
|
August 19, 2022 | Not Applicable |
NCT02579564 | Xinqiao Hospital of Chongqing |
Malignant Hydrothorax|Non Small Cell Lung Cancer
|
October 2016 | Phase 3 |
NCT01376310 | Novartis Pharmaceuticals|Novartis |
Cancer
|
November 2, 2010 | Phase 2 |
NCT00227630 | European Organisation for Research and Treatment of Cancer - EORTC |
Malignant Mesothelioma
|
July 2005 | Phase 2 |
NCT02535312 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Refractory Malignant Solid Neoplasm|Unresectable Solid Neoplasm
|
August 11, 2015 | Phase 1|Phase 2 |
NCT04267848 | National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Squamous Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8
|
June 3, 2020 | Phase 3 |
NCT02710396 | Naiyer Rizvi|Merck Sharp & Dohme LLC|Massachusetts General Hospital|National Cancer Institute (NCI)|Columbia University |
Carcinoma, Non-Small-Cell Lung
|
May 31, 2016 | Phase 2 |
NCT02489903 | EpicentRx, Inc. |
Small Cell Carcinoma|Carcinoma, Non-Small-Cell Lung|Neuroendocrine Tumors|Ovarian Epithelial Cancer
|
June 2015 | Phase 2 |
NCT00789373 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
November 2008 | Phase 3 |
NCT02162537 | Centre Hospitalier Intercommunal Creteil|Groupe Francais De Pneumo-Cancerologie |
Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer|Adenocarcinoma of Lung Metastatic to Brain|Cerebral Metastases
|
December 2013 | Phase 3 |
NCT04993677 | Seagen Inc.|Merck Sharp & Dohme LLC |
Melanoma|Carcinoma, Non-Small- Cell Lung
|
October 6, 2021 | Phase 2 |
NCT05346952 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Advanced Non-squamous Non-small Cell Lung Cancer
|
January 25, 2022 | Phase 3 |
NCT02980991 | Fudan University |
Lung Adenocarcinoma
|
December 2015 | Phase 2 |
NCT00461786 | Eli Lilly and Company|Gynecologic Oncology Group |
Ovarian Cancer|Peritoneal Cancer
|
September 2004 | Phase 2 |
NCT02964013 | Merck Sharp & Dohme LLC |
Neoplasms
|
December 13, 2016 | Phase 1 |
NCT03134872 | Jiangsu HengRui Medicine Co., Ltd. |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Lung Diseases|Respiratory Tract Disease|Neoplasms by Site|Neoplasm, Bronchial|Carcinoma, Bronchogenic
|
May 12, 2017 | Phase 3 |
NCT02787473 | First People´s Hospital of Hangzhou |
Squamous Cell Lung Cancer
|
October 2016 | Phase 2 |
NCT02886195 | Fujian Cancer Hospital |
EGFR Gene Mutation
|
July 2016 | Phase 3 |
NCT02723955 | GlaxoSmithKline|Merck Sharp & Dohme LLC |
Neoplasms
|
June 23, 2016 | Phase 1 |
NCT01005680 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2009 | Phase 3 |
NCT03715933 | Inhibrx, Inc. |
Solid Tumors|Malignant Pleural Mesothelioma|Gastric Adenocarcinoma|Colorectal Adenocarcinoma|Sarcoma|Pancreatic Adenocarcinoma|Ewing Sarcoma|Chondrosarcoma
|
October 10, 2018 | Phase 1 |
NCT01020786 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2009 | Phase 4 |
NCT02607592 | Sun Yat-sen University |
Carcinoma?Non-Small-Cell Lung
|
August 2015 | Phase 3 |
NCT02707666 | University of Chicago |
Pleural Mesothelioma
|
February 25, 2016 | Phase 1 |
NCT03918278 | Merck Sharp & Dohme LLC |
Neoplasms
|
June 19, 2019 | Phase 1 |
NCT00071136 | Eli Lilly and Company |
Lung Neoplasms
|
December 2003 | Phase 1|Phase 2 |
NCT04892953 | M.D. Anderson Cancer Center |
Stage III Lung Cancer AJCC v8|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IIIC Lung Cancer AJCC v8
|
July 31, 2021 | Phase 2 |
NCT00950365 | Albert Einstein College of Medicine|National Cancer Institute (NCI)|Eli Lilly and Company|OSI Pharmaceuticals |
Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
April 2006 | Phase 2 |
NCT02817633 | Tesaro, Inc. |
Neoplasms
|
July 8, 2016 | Phase 1 |
NCT02624700 | Virginia Commonwealth University|Eli Lilly and Company|Bayer |
Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer
|
January 28, 2016 | Phase 2 |
NCT00454649 | Pfizer |
Neoplasms
|
December 2005 | Phase 1 |
NCT05298176 | Amsterdam UMC, location VUmc |
Non-Small Cell Lung Cancer
|
January 4, 2022 | Phase 2 |
NCT04297605 | University of Rochester |
Non-small Cell Lung Cancer
|
May 15, 2020 | Phase 1 |
NCT03976323 | Merck Sharp & Dohme LLC |
Carcinoma, Non-squamous Non-small-cell Lung
|
June 28, 2019 | Phase 3 |
NCT04762459 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Jiangsu Hansoh Pharmaceutical Co., Ltd.|GeneCast Biotechnology Co., Ltd. |
Non-small Cell Lung Carcinoma
|
August 1, 2021 | Phase 3 |
NCT00070473 | Children´s Oncology Group|National Cancer Institute (NCI) |
Unspecified Childhood Solid Tumor, Protocol Specific
|
October 2003 | Phase 1 |
NCT00533429 | Eli Lilly and Company|Genentech, Inc. |
Non-small Cell Lung Cancer
|
October 2007 | Phase 2 |
NCT00949650 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung|Adenocarcinoma
|
August 14, 2009 | Phase 3 |
NCT00497315 | University Hospital, Antwerp|Universiteit Antwerpen|Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
February 2006 | Phase 2 |
NCT02134912 | Southwest Oncology Group|National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
August 2014 | Phase 2 |
NCT00864513 | Georgetown University|Eli Lilly and Company |
Pancreas Cancer
|
October 2007 | Phase 2 |
NCT00612677 | H. Lee Moffitt Cancer Center and Research Institute|Sanofi |
Lung Cancer
|
June 2007 | Phase 2 |
NCT00102804 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
March 2005 | Phase 3 |
NCT02397928 | NovoCure Ltd. |
Malignant Pleural Mesothelioma
|
February 2015 | Phase 2 |
NCT00389688 | European Organisation for Research and Treatment of Cancer - EORTC |
Lung Cancer
|
August 2006 | Phase 2 |
NCT04530227 | Tianjin Medical University Cancer Institute and Hospital |
Early Stage Non-small Cell Lung Cancer
|
September 25, 2020 | Phase 2 |
NCT03530397 | MedImmune LLC |
Selected Advanced Solid Tumors
|
April 24, 2018 | Phase 1 |
NCT02725918 | Guangdong Association of Clinical Trials |
Non-small Cell Lung Cancer
|
April 1, 2016 | Phase 2 |
NCT00745875 | AstraZeneca |
Non Small Cell Lung Cancer|Lung Cancer
|
August 2008 | Phase 2 |
NCT03631199 | Novartis Pharmaceuticals|Novartis |
Non-small Cell Lung Cancer
|
December 21, 2018 | Phase 3 |
NCT00487669 | Dartmouth-Hitchcock Medical Center|CTI BioPharma |
Advanced Non-small Cell Lung Cancer
|
October 2006 | Phase 2 |
NCT04619797 | Hoffmann-La Roche |
Non-small Cell Lung Cancer (NSCLC)
|
December 14, 2020 | Phase 2|Phase 3 |
NCT00660816 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
January 2008 | Phase 2 |
NCT05504278 | Innovent Biologics (Suzhou) Co. Ltd. |
Advanced Non-Small Cell Lung Cancer
|
August 31, 2022 | Phase 1 |
NCT00692159 | Tracon Pharmaceuticals Inc. |
Neoplasm
|
June 2008 | Phase 1 |
NCT02439450 | Heat Biologics |
Non-small Cell Lung Cancer
|
April 15, 2015 | Phase 1|Phase 2 |
NCT01041781 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
February 2010 | Phase 3 |
NCT03626922 | NSABP Foundation Inc|Merck Sharp & Dohme LLC|Eli Lilly and Company |
Metastatic Colorectal Cancer
|
May 15, 2019 | Phase 1 |
NCT03425643 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
April 24, 2018 | Phase 3 |
NCT00703976 | University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. |
Cancer
|
October 2008 | Phase 2 |
NCT05335941 | M.D. Anderson Cancer Center |
Urothelial Carcinoma|Metastatic Cancer
|
September 30, 2022 | Phase 2 |
NCT05059522 | Pfizer |
Advanced Malignancies|NSCLC|Ovarian Cancer|Urothelial Cancer|Solid Tumors
|
September 29, 2021 | Phase 3 |
NCT03489616 | Shandong Cancer Hospital and Institute |
Carcinoma, Non-Small-Cell Lung
|
January 15, 2018 | Not Applicable |
NCT00614822 | Christiana Care Health Services|Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2007 | Phase 2 |
NCT03846310 | Arcus Biosciences, Inc.|Gilead Sciences |
Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer|Nonsquamous Nonsmall Cell Neoplasm of Lung|Sensitizing EGFR Gene Mutation
|
April 1, 2019 | Phase 1 |
NCT00192088 | Eli Lilly and Company |
Advanced Gastric Carcinoma
|
May 2004 | Phase 2 |
NCT00859495 | Columbia University |
Pleural Mesothelioma
|
February 2008 | Phase 2 |
NCT00193414 | SCRI Development Innovations, LLC|Eli Lilly and Company |
Lung Cancer
|
May 2005 | Phase 2 |
NCT04047862 | BeiGene |
Locally Advanced and Metastatic Solid Tumors
|
August 26, 2019 | Phase 1 |
NCT02117167 | UNICANCER|Intergroupe Francophone de Cancerologie Thoracique|Fondation ARC|AstraZeneca |
Non-small Cell Lung Cancer Metastatic
|
April 23, 2014 | Phase 2 |
NCT02574078 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
November 23, 2015 | Phase 1|Phase 2 |
NCT04943029 | Wuhan Union Hospital, China |
Non Small Cell Lung Cancer
|
August 20, 2021 | Phase 2 |
NCT00308750 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
March 2006 | Phase 2 |
NCT00440414 | Hellenic Oncology Research Group|University Hospital of Crete |
Non Small Cell Lung Cancer
|
April 2006 | Phase 3 |
NCT00297089 | AbbVie (prior sponsor, Abbott)|AbbVie |
Lung Cancer|NSCLC|Non-Small-Cell Lung Cancer
|
November 2006 | Phase 1|Phase 2 |
NCT03647956 | The University of Hong Kong |
NSCLC Stage IIIB|NSCLC Stage IV|EGFR Activating Mutation
|
October 1, 2018 | Phase 2 |
NCT00994097 | AGC Biologics S.p.A. |
Non-small Cell Lung Cancer
|
July 2009 | Phase 2 |
NCT03137771 | NRG Oncology|National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer
|
April 7, 2017 | Phase 2 |
NCT00733031 | AstraZeneca |
Cancer,|Solid Tumors|Advanced Solid Malignancies
|
August 2008 | Phase 1 |
NCT05358548 | Rutgers, The State University of New Jersey |
Head and Neck Cancer|Lung Cancer
|
April 28, 2022 | Phase 2 |
NCT00040625 | Eli Lilly and Company |
Mesothelioma
|
||
NCT00290017 | Point Therapeutics |
Carcinoma, Non-Small-Cell Lung|Lung Cancer|Neoplasms, Lung|Neoplasms, Pulmonary
|
February 2006 | Phase 3 |
NCT00087113 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
August 2004 | Phase 2 |
NCT00807573 | Memorial Sloan Kettering Cancer Center |
Lung Cancer
|
December 2008 | Phase 2 |
NCT00324805 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group |
Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7
|
June 1, 2007 | Phase 3 |
NCT01633970 | Genentech, Inc. |
Cancer
|
July 11, 2012 | Phase 1 |
NCT03348904 | Incyte Corporation|Bristol-Myers Squibb |
Lung Cancer
|
December 27, 2017 | Phase 3 |
NCT04092283 | National Cancer Institute (NCI) |
Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma
|
April 9, 2020 | Phase 3 |
NCT03706703 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
Lung Cancer
|
October 1, 2018 | Phase 2 |
NCT00190983 | Eli Lilly and Company|Gynecologic Oncology Group |
Cervical Intraepithelial Neoplasia|Uterine Neoplasms|Genital Neoplasms, Female
|
February 2005 | Phase 2 |
NCT00497770 | Eli Lilly and Company |
Lung Neoplasms
|
February 2007 | |
NCT00265785 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
July 2006 | Phase 2 |
NCT01481259 | People´s Hospital of Guangxi |
Non-small Cell Lung Cancer
|
January 2010 | Phase 2|Phase 3 |
NCT01742767 | Universität Duisburg-Essen|Eli Lilly and Company |
NSCLC
|
November 2012 | Phase 2 |
NCT03840902 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Non-small Cell Lung Cancer
|
April 16, 2019 | Phase 2 |
NCT04339218 | Institut Bergonié |
Lung Adenocarcinoma|Cryotherapy Effect
|
August 28, 2020 | Phase 3 |
NCT02357147 | Morphotek |
Mesothelioma, Malignant
|
November 3, 2015 | Phase 2 |
NCT02093962 | Threshold Pharmaceuticals|EMD Serono |
Non-small Cell Lung Cancer
|
June 2014 | Phase 2 |
NCT02531854 | Advaxis, Inc. |
Carcinoma, Non-Small-Cell Lung
|
December 2016 | Phase 2 |
NCT01170871 | University of Southern California |
Advanced Solid Tumors
|
Phase 1 | |
NCT00191191 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
October 2004 | Phase 2 |
NCT01674738 | Aktion Bronchialkarzinom e.V.|Roche Pharma AG|Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung
|
Phase 2 | |
NCT01982955 | Merck KGaA, Darmstadt, Germany |
Non-small Cell Lung Cancer
|
December 23, 2013 | Phase 1|Phase 2 |
NCT04022876 | Aileron Therapeutics, Inc. |
Non Small Cell Lung Cancer|Small-cell Lung Cancer
|
September 3, 2019 | Phase 1 |
NCT02998528 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Non Small Cell Lung Cancer
|
March 4, 2017 | Phase 3 |
NCT00087087 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
July 2004 | Phase 2 |
NCT00886678 | Zhejiang Cancer Hospital |
Non-Small Cell Lung Cancer
|
July 2008 | Phase 2 |
NCT01935947 | National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
May 2013 | Phase 2 |
NCT00383266 | Washington University School of Medicine|Eli Lilly and Company |
Esophageal Neoplasms
|
October 2006 | Phase 2 |
NCT00528281 | GlaxoSmithKline |
Lung Cancer, Non-Small Cell
|
September 20, 2007 | Phase 1 |
NCT02639091 | Bayer |
Medical Oncology
|
February 3, 2016 | Phase 1 |
NCT02899299 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Mesothelioma
|
November 29, 2016 | Phase 3 |
NCT04989283 | National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Superior Sulcus Lung Carcinoma
|
September 9, 2021 | Phase 2 |
NCT00940069 | Hunan Province Tumor Hospital |
Non-small-cell Lung Cancer|Adenocarcinoma
|
March 2009 | Phase 2 |
NCT00560573 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
November 2007 | Phase 1 |
NCT00892710 | SCRI Development Innovations, LLC|Genentech, Inc. |
Non Small Cell Lung Cancer
|
June 2009 | Phase 2 |
NCT00006007 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
December 2000 | Phase 2 |
NCT00096187 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Gestational Trophoblastic Tumor
|
July 2005 | Phase 2 |
NCT00111839 | EMD Serono |
Lung Cancer|Non Small Cell Lung Carcinoma
|
May 31, 2005 | Phase 2 |
NCT04716933 | Merck Sharp & Dohme LLC|Eisai Inc. |
Nonsquamous Non-small Cell Lung Cancer
|
November 5, 2019 | Phase 3 |
NCT00529100 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
December 2005 | Phase 1|Phase 2 |
NCT05185544 | Shanghai Zhongshan Hospital |
Sensitivity
|
January 1, 2022 | |
NCT01088620 | WiSP Wissenschaftlicher Service Pharma GmbH|Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Carcinoma, Non-Small-Cell Lung
|
April 2010 | Phase 2 |
NCT05132985 | Liaoning Tumor Hospital & Institute |
NSCLC|EGF-R Positive Non-Small Cell Lung Cancer
|
January 1, 2022 | Phase 2 |
NCT00377520 | Eli Lilly and Company|Gynecologic Oncology Group |
Neoplasms|Neoplasms by Site|Urogenital Neoplasms|Genital Neoplasms, Female|Uterine Neoplasms|Endometrial Neoplasms|Cancer of Endometrium|Endometrial Cancer|Cancer of the Endometrium|Endometrium Cancer|Neoplasms, Endometrial
|
September 2006 | Phase 2 |
NCT05200481 | Intergroupe Francophone de Cancerologie Thoracique |
Non Small Cell Lung Cancer|ALK Gene Mutation
|
May 18, 2022 | Phase 2 |
NCT02383212 | Regeneron Pharmaceuticals|Sanofi |
Advanced Cancer|Advanced Malignancies
|
February 2, 2015 | Phase 1 |
NCT00191347 | Eli Lilly and Company |
Breast Cancer
|
October 2004 | Phase 2 |
NCT00932893 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
September 2009 | Phase 3 |
NCT04220892 | Jose Carrillo|Eli Lilly and Company|Saint John´s Cancer Institute |
High Grade Glioma
|
July 8, 2020 | Early Phase 1 |
NCT01333696 | Fudan University |
Squamous Cell Carcinoma of Head and Neck
|
April 2011 | Phase 2 |
NCT01042288 | SCRI Development Innovations, LLC|Amgen |
Non-Small-Cell Lung Cancer
|
June 2010 | Phase 2 |
NCT05198830 | National Cancer Institute (NCI) |
Lung Adenocarcinoma|Lung Large Cell Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8
|
May 20, 2022 | Phase 2 |
NCT01172028 | University of Arizona|National Cancer Institute (NCI) |
Breast Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer
|
September 2005 | Phase 1 |
NCT03866980 | Akeso|Akeso Tiancheng, Inc |
Lung Cancer Non-small Cell Stage IV
|
November 27, 2018 | Phase 3 |
NCT03768037 | Guangdong Association of Clinical Trials |
Advanced Non-squamous NSCLC
|
November 26, 2018 | Phase 4 |
NCT01301716 | Genentech, Inc. |
Solid Cancers
|
September 2011 | Phase 1 |
NCT00732992 | Pfizer |
Neoplasm, Malignant
|
August 2008 | Phase 1 |
NCT04861948 | Innovent Biologics (Suzhou) Co. Ltd. |
Solid Tumors|Lung Adenocarcinoma|Osteosarcoma
|
May 25, 2021 | Phase 1 |
NCT01000480 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
October 2009 | Phase 2 |
NCT00407550 | Mayo Clinic|National Cancer Institute (NCI) |
Lung Cancer
|
November 2006 | Phase 2 |
NCT00771953 | University of Maryland, Baltimore|Tragara Pharmaceuticals, Inc. |
Lung Cancer|Non Small Cell Lung Cancer
|
November 2008 | Phase 2 |
NCT04158141 | NRG Oncology|National Cancer Institute (NCI) |
Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Stage I Pleural Malignant Mesothelioma AJCC v8|Stage IA Pleural Malignant Mesothelioma AJCC v8|Stage IB Pleural Malignant Mesothelioma AJCC v8|Stage II Pleural Malignant Mesothelioma AJCC v8|Stage IIIA Pleural Malignant Mesothelioma AJCC v8
|
January 29, 2020 | Phase 3 |
NCT00034606 | Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms|Neoplasms
|
Phase 2 | |
NCT01401192 | Samsung Medical Center |
Non-small Cell Lung Cancer
|
July 2011 | Phase 2 |
NCT04077463 | Janssen Research & Development, LLC |
Carcinoma, Non-Small-Cell Lung
|
September 4, 2019 | Phase 1 |
NCT01705184 | Intergroupe Francophone de Cancerologie Thoracique |
Non-small Cell Lung Cancer Metastatic|Nonsquamous Nonsmall Cell Neoplasm of Lung
|
December 2012 | Phase 2 |
NCT00470405 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lymphoma|Solid Tumor
|
May 2004 | Phase 1 |
NCT01450384 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor
|
October 2011 | Phase 1 |
NCT00684099 | Hellenic Oncology Research Group|University Hospital of Crete |
Non Small Cell Lung Cancer
|
May 2006 | Phase 1|Phase 2 |
NCT03101579 | The First Hospital of Jilin University |
Leptomeningeal Metastases
|
March 1, 2017 | Phase 1 |
NCT01338792 | University of Southern California|National Cancer Institute (NCI) |
Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer
|
June 2006 | Phase 2 |
NCT02591615 | Alliance Foundation Trials, LLC.|Merck Sharp & Dohme LLC |
Non-Small Cell Lung Cancer
|
March 2016 | Phase 2 |
NCT04203511 | Incyte Corporation |
Non-small Cell Lung Cancer
|
July 31, 2020 | Phase 3 |
NCT04194944 | Loxo Oncology, Inc.|Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
February 17, 2020 | Phase 3 |
NCT03366064 | Asan Medical Center|Korea Research Institute of Bioscience & Biotechnology |
Non-small Cell Lung Cancer
|
November 9, 2017 | Phase 1 |
NCT05498428 | Janssen Research & Development, LLC |
Carcinoma, Non-small-Cell Lung
|
December 2, 2022 | Phase 2 |
NCT00806819 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
December 2008 | Phase 3 |
NCT00035061 | Eli Lilly and Company |
Urologic Neoplasms|Metastases, Neoplasm
|
Phase 2 | |
NCT04611776 | Hoffmann-La Roche |
Carcinoma, Non-Small Cell Lung
|
July 1, 2021 | Phase 2 |
NCT01442909 | Taipei Veterans General Hospital, Taiwan |
Non-small-cell Lung Cancer
|
March 2008 | Phase 4 |
NCT02284490 | Rongjie Tao|National Natural Science Foundation of China|Shandong Cancer Hospital and Institute |
Brain Metastases
|
November 2014 | Phase 2 |
NCT04736823 | Akeso |
NSCLC
|
February 1, 2021 | Phase 2 |
NCT02603003 | Shanghai University of Traditional Chinese Medicine |
Non-small Cell Lung Cancer(NSCLC)
|
June 2015 | Phase 1 |
NCT00507858 | M.D. Anderson Cancer Center|Eli Lilly and Company |
Head and Neck Cancer
|
September 2005 | Phase 1 |
NCT02194738 | National Cancer Institute (NCI) |
Lung Adenocarcinoma|Lung Large Cell Carcinoma|Resectable Lung Non-Small Cell Carcinoma|Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage IB Lung Squamous Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage II Lung Squamous Cell Carcinoma AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIA Lung Squamous Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Squamous Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
|
August 18, 2014 | Not Applicable |
NCT05116462 | Innovent Biologics (Suzhou) Co. Ltd. |
Non-small Cell Lung Cancer (NSCLC)
|
November 11, 2021 | Phase 3 |
NCT01447225 | Merrimack Pharmaceuticals|Sanofi |
Solid Tumors
|
October 2011 | Phase 1 |
NCT00424242 | Northwestern University|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Metastatic Cancer|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis|Unspecified Adult Solid Tumor, Protocol Specific
|
January 2007 | Early Phase 1 |
NCT00268437 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Esophageal Cancer
|
April 2006 | Phase 2 |
NCT01064648 | National Cancer Institute (NCI) |
Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma
|
March 15, 2010 | Phase 1|Phase 2 |
NCT03955042 | Saint John´s Cancer Institute|Eli Lilly and Company|Chordoma Foundation |
Chordoma
|
September 6, 2019 | Phase 1 |
NCT04054531 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Non-small Cell Lung Cancer
|
September 4, 2019 | Phase 2 |
NCT00281125 | Nevada Cancer Institute |
Non-Small Cell Lung Cancer and Pleural Mesothelioma
|
January 2006 | Phase 1|Phase 2 |
NCT03178552 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
September 22, 2017 | Phase 2|Phase 3 |
NCT00520936 | Eli Lilly and Company|Children´s Oncology Group |
Osteosarcoma|Medulloblastoma|Sarcoma, Ewing´s|Neuroblastoma (Measurable Disease)|Neuroblastoma (Metaiodobenzylguanidine|Positive Evaluable)|Rhabdomyosarcoma|Ependymoma|Non-brainstem High-grade Glioma
|
September 2007 | Phase 2 |
NCT03088540 | Regeneron Pharmaceuticals|Sanofi |
Carcinoma?Non-Small-Cell Lung|Lung Carcinomas, Non-Small-Cell|Non-small-cell Lung Carcinoma|Nonsmall Cell Lung Cancer
|
May 29, 2017 | Phase 3 |
NCT00117962 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Eli Lilly and Company|Bristol-Myers Squibb |
Lung Cancer
|
September 2005 | Phase 2 |
NCT00982111 | Eli Lilly and Company|Quintiles, Inc.|Parexel|PPD|Medidata Solutions|Laboratory Corporation of America|University of Colorado, Denver|Thermo Fisher Scientific, Inc|Pacific Biomarkers|Intertek|Sysmex Inostics GmbH |
Non Small Cell Lung Cancer
|
November 2, 2009 | Phase 3 |
NCT00005636 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Malignant Mesothelioma
|
November 1999 | Phase 3 |
NCT00438204 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lung Cancer
|
May 2006 | Phase 2 |
NCT00907179 | University of Pittsburgh|Novartis Pharmaceuticals |
Non-Small Cell Lung Cancer
|
July 2009 | Phase 1 |
NCT00976456 | PD Dr. med. Wolfgang Schuette|Roche Pharma AG|Eli Lilly and Company|Martha-Maria Krankenhaus Halle-Dölau gGmbH |
Non-squamous Non-small Cell Lung Cancer
|
September 2009 | Phase 3 |
NCT05364645 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
July 25, 2022 | Phase 2 |
NCT05477615 | Jin Hyoung Kang|Korea University Anam Hospital|Seoul St. Mary´s Hospital |
Non-small Cell Lung Cancer
|
August 2022 | Phase 2 |
NCT02477826 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Non-Small Cell Lung Cancer
|
August 5, 2015 | Phase 3 |
NCT04061590 | University of California, San Francisco|Merck Sharp & Dohme LLC |
Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8
|
May 29, 2020 | Phase 2 |
NCT01139775 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
February 2011 | Phase 1|Phase 2 |
NCT03456076 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
August 16, 2018 | Phase 3 |
NCT02182102 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
September 2005 | Phase 1 |
NCT04459611 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Non-small Cell Lung Cancer
|
July 1, 2020 | Phase 2 |
NCT01001910 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
July 2008 | Phase 2 |
NCT03460678 | Hikma Pharmaceuticals LLC |
Carcinoma, Non-Small-Cell Lung
|
February 28, 2018 | Phase 4 |
NCT03164616 | AstraZeneca |
Non Small Cell Lung Cancer NSCLC
|
June 1, 2017 | Phase 3 |
NCT00863512 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
March 2009 | Phase 3 |
NCT00891579 | Chinese Society of Lung Cancer |
Non Small Cell Lung Cancer
|
February 2009 | Phase 2 |
NCT01803282 | Gilead Sciences |
Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer
|
March 29, 2013 | Phase 1 |
NCT01840579 | Merck Sharp & Dohme LLC |
Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer
|
April 26, 2013 | Phase 1 |
NCT03507244 | The First Hospital of Jilin University |
Leptomeningeal Metastasis
|
April 12, 2018 | Phase 1|Phase 2 |
NCT00087100 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Cancer
|
May 2006 | Phase 2 |
NCT03872661 | Sun Yat-sen University |
Lung Cancer Stage III
|
March 1, 2019 | Phase 2 |
NCT05209620 | Henan Cancer Hospital |
Central Nervous System Lymphoma
|
December 21, 2021 | Phase 2 |
NCT04846452 | The First Affiliated Hospital with Nanjing Medical University |
Metastatic NSCLC|Recurrent NSCLC|Advanced Non-Small Cell Squamous Lung Cancer
|
June 1, 2021 | Phase 2 |
NCT00251524 | Veeda Oncology|Sanofi|Eli Lilly and Company|Genentech, Inc. |
Non-Small Cell Lung Cancer
|
November 2005 | Phase 2 |
NCT02921984 | Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University |
Salivary Gland Tumors|Head and Neck Cancer
|
September 2013 | Phase 1 |
NCT02535325 | National Cancer Institute (NCI) |
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Adenocarcinoma AJCC v7|Stage III Lung Large Cell Carcinoma AJCC v7|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Adenocarcinoma AJCC v7|Stage IIIA Lung Large Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Adenocarcinoma AJCC v7|Stage IIIB Lung Large Cell Carcinoma AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Adenocarcinoma AJCC v7|Stage IV Lung Large Cell Carcinoma AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7
|
September 30, 2015 | Phase 1 |
NCT04686305 | AstraZeneca|Daiichi Sankyo, Inc. |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
March 9, 2021 | Phase 1 |
NCT04816214 | Novartis Pharmaceuticals|Novartis |
Carcinoma, Non-Small-Cell Lung
|
September 22, 2021 | Phase 3 |
NCT02542293 | AstraZeneca |
Non Small Cell Lung Carcinoma NSCLC
|
November 3, 2015 | Phase 3 |
NCT04265534 | Calithera Biosciences, Inc |
Non-Small Cell Lung Cancer|Non-squamous Non-small-cell Lung Cancer|Non-Squamous Non-Small Cell Neoplasm of Lung|KEAP1 Gene Mutation|NRF2 Gene Mutation|NFE2L2 Gene Mutation
|
July 24, 2020 | Phase 2 |
NCT03366766 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University |
Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage II Non-Small Cell Lung Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer
|
December 20, 2017 | Phase 2 |
NCT00794417 | Regeneron Pharmaceuticals|Sanofi |
Advanced Carcinoma|Non-small Cell Lung Cancer
|
November 30, 2008 | Phase 1|Phase 2 |
NCT03062800 | Qilu Hospital of Shandong University |
Advanced Nsclc
|
December 2016 | Phase 2 |
NCT00234052 | Northwestern University|National Cancer Institute (NCI) |
Lung Cancer
|
July 28, 2005 | Phase 2 |
NCT00550173 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
November 2007 | Phase 2 |
NCT05299125 | Latin American Cooperative Oncology Group|Janssen, LP |
Metastatic Non-small Cell Lung Cancers
|
November 2022 | Phase 2 |
NCT00482014 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
May 2007 | Phase 1|Phase 2 |
NCT05624996 | NRG Oncology|National Cancer Institute (NCI) |
Locally Advanced Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8
|
June 9, 2023 | Phase 3 |
NCT00276783 | Northwestern University|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer
|
November 2005 | Phase 2 |
NCT00712062 | University of Florida |
Primary Central Nervous System Lymphoma
|
February 2009 | Phase 2 |
NCT00363415 | Eli Lilly and Company |
Small Cell Lung Cancer
|
August 2006 | Phase 3 |
NCT00190801 | Eli Lilly and Company |
Gastrointestinal Neoplasms
|
September 2003 | Phase 2 |
NCT01850303 | Intergroupe Francophone de Cancerologie Thoracique |
Non Small Cell Lung Cancer (Squamous or Non Squamous)
|
May 16, 2013 | Phase 3 |
NCT04989322 | Dr Joanne CHIU|The University of Hong Kong |
Nsclc|EGFR Activating Mutation|EGF-R Positive Non-Small Cell Lung Cancer|ALK Gene Rearrangement Positive|ROS1 Gene Rearrangement|ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer
|
October 5, 2021 | Phase 2 |
NCT00079872 | Eli Lilly and Company |
Colorectal Cancer
|
February 2004 | Phase 2 |
NCT03562871 | IO Biotech|Merck Sharp & Dohme LLC |
NSCLC
|
August 22, 2018 | Phase 1|Phase 2 |
NCT04222972 | Hoffmann-La Roche |
RET-fusion Non Small Cell Lung Cancer|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Diseases|Head and Neck Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve Tissue
|
July 24, 2020 | Phase 3 |
NCT04929041 | National Cancer Institute (NCI) |
Advanced Lung Adenocarcinoma|Advanced Lung Adenosquamous Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Adenocarcinoma|Metastatic Lung Adenosquamous Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
December 21, 2021 | Phase 2|Phase 3 |
NCT00691301 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
September 2008 | Phase 2 |
NCT00370292 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
September 2006 | Phase 2 |
NCT03566576 | Fujian Cancer Hospital |
Non-squamous Non-small Cell Lung Cancer
|
July 1, 2018 | Not Applicable |
NCT03700333 | The First Affiliated Hospital with Nanjing Medical University |
Carcinoma, Non-Small-Cell Lung
|
October 20, 2018 | Phase 3 |
NCT00087711 | Eli Lilly and Company |
Non Small Cell Lung Carcinoma
|
July 2004 | Phase 3 |
NCT01105390 | National Cancer Institute (NCI) |
Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma
|
April 2010 | Phase 2 |
NCT00216099 | Christopher Sweeney, MBBS|Eli Lilly and Company|Walther Cancer Institute|Hoosier Cancer Research Network |
Prostate Cancer
|
February 2005 | Phase 2 |
NCT00321308 | Pfizer |
Carcinoma, Non-Small Cell Lung
|
September 2006 | Phase 2 |
NCT00614965 | Hellenic Oncology Research Group|University Hospital of Crete |
Non Small Cell Lung Cancer
|
November 2006 | Phase 2 |
NCT00415636 | Eli Lilly and Company |
Cancer
|
January 2007 | Phase 1 |
NCT04262869 | Emory University|National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
March 27, 2020 | Phase 2 |
NCT01784549 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Azienda Sanitaria Locale di Cagliari|Azienda Ospedaliera San Gerardo di Monza|Ospedale Santa Croce-Carle Cuneo|Azienda Ospedaliera S. Maria della Misericordia|Istituto Tumori Giovanni Paolo II, BARI|Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, Napoli|Azienda Ospedaliera Santa Maria Degli Angeli|Azienda Ospedaliera San Camillo Forlanini|Azienda Ospedaliera San Giovanni Battista|Azienda Ospedaliera Universitaria Integrata Verona|Azienda Sanitaria Locale n.2 Savonese|ASL TO4, Chivasso|Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento|Istituto Clinico Humanitas|Azienda Ospedaliera Sant´Andrea|Azienda Ospedaliera, Ospedale Civile di Legnano|Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno |
Non Small Cell Lung Cancer
|
July 2012 | Phase 2 |
NCT00703638 | Masonic Cancer Center, University of Minnesota |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma
|
May 2008 | Phase 1 |
NCT00191750 | Eli Lilly and Company |
Carcinoma, Small Cell
|
July 2004 | Phase 2 |
NCT04856176 | Tufts Medical Center|Partner Therapeutics, Inc. |
Advanced Lung Non-Small Cell Carcinoma|Non-Small Cell Carcinoma of Lung, TNM Stage 4
|
January 3, 2022 | Phase 2 |
NCT00545948 | Duke University|Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung
|
December 2007 | Phase 2 |
NCT03987867 | Tianjin Medical University Cancer Institute and Hospital |
Non-small Cell Lung Cancer|First-line Treatment
|
June 1, 2019 | Phase 1 |
NCT01860040 | Western Regional Medical Center |
Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer|Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
|
April 2013 | Phase 2 |
NCT00506051 | Genzyme, a Sanofi Company|Sanofi |
Carcinoma|Non-Small Cell Lung|Lung Cancer
|
July 2005 | Phase 1 |
NCT01579630 | Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital|Taichung Veterans General Hospital|China Medical University Hospital|Dalin Tzu Chi General Hospital|Tri-Service General Hospital |
NSCLC
|
March 2011 | Phase 2|Phase 3 |
NCT00989690 | Istituto Scientifico H. San Raffaele|National Cancer Institute (NCI) |
Lung Cancer
|
February 2008 | Phase 3 |
NCT02120807 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Stage IV Lung Adenocarcinoma
|
April 2014 | Phase 1 |
NCT02211833 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
October 2006 | Phase 1 |
NCT02944396 | AbbVie |
Non-Small Cell Lung Cancer
|
December 23, 2016 | Phase 1 |
NCT00179699 | Celgene Corporation|Prologue Research International|Celgene |
Non-Small Cell Lung Cancer
|
September 2005 | Phase 1 |
NCT03840915 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Carcinoma, Non-Small-Cell Lung
|
April 2, 2019 | Phase 1|Phase 2 |
NCT00520676 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
October 2007 | Phase 3 |
NCT04379635 | BeiGene |
Non Small Cell Lung Cancer
|
May 29, 2020 | Phase 3 |
NCT01953419 | Sun Yat-sen University |
Gastric Cancer
|
September 2010 | Phase 2 |
NCT04695925 | Li Zhang, MD|Sun Yat-sen University |
Non-small Cell Carcinoma|EGFR Gene Mutation
|
January 4, 2021 | Phase 3 |
NCT00391274 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
October 2006 | Phase 3 |
NCT00769600 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Recurrent Non Small Cell Lung Cancer
|
November 2008 | Phase 2 |
NCT01666977 | Amgen |
Non Small Cell Lung Cancer
|
August 2012 | Phase 1|Phase 2 |
NCT00325234 | Eli Lilly and Company |
Breast Cancer
|
June 2006 | Phase 2 |
NCT01192243 | Fudan University |
Toxicity|Non-small Cell Lung Cancer
|
December 2009 | Phase 2 |
NCT00906282 | SCRI Development Innovations, LLC|Eli Lilly and Company |
Non Small Cell Lung Cancer
|
June 2009 | Phase 2 |
NCT02609776 | Janssen Research & Development, LLC |
Non-Small-Cell Lung Cancer
|
May 24, 2016 | Phase 1 |
NCT03737994 | National Cancer Institute (NCI)|NRG Oncology |
Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
April 1, 2019 | Phase 2 |
NCT00408226 | CASI Pharmaceuticals, Inc. |
Advanced Cancer|Non-Small Cell Lung Cancer
|
October 2006 | Phase 1|Phase 2 |
NCT03085914 | Incyte Corporation |
Solid Tumor
|
May 2, 2017 | Phase 1|Phase 2 |
NCT00503997 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 2006 | Phase 2 |
NCT00523419 | Eli Lilly and Company |
Osteosarcoma
|
September 2007 | Phase 2 |
NCT04129502 | Takeda |
Advanced+Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
January 10, 2020 | Phase 3 |
NCT00798603 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
December 2008 | Phase 2 |
NCT01313663 | GlaxoSmithKline |
Lung Cancer, Small Cell
|
February 2011 | Phase 2 |
NCT00222729 | University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. |
Cancer
|
November 2005 | Phase 2 |
NCT04405674 | Shanghai Chest Hospital |
Non Small Cell Lung Cancer
|
July 15, 2020 | Phase 2 |
NCT04533451 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Metastatic Lung Adenocarcinoma|Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
October 1, 2020 | Phase 2 |
NCT00227539 | University of Washington|National Cancer Institute (NCI) |
Lung Cancer
|
July 2005 | Phase 2 |
NCT01336842 | University of California, Davis|Novartis Pharmaceuticals |
Solid Tumors|Non-Small Cell Lung Cancer (NSCLC)
|
April 2011 | Phase 1 |
NCT02076477 | Sichuan Cancer Hospital and Research Institute|Mianyang Central Hospital|Cancer Hospital of Guizhou Province |
Oligo-metastatic Stage IV Non-small Cell Lung Cancer
|
January 2014 | Phase 3 |
NCT03351842 | Shanghai Pulmonary Hospital, Shanghai, China |
Chemotherapy, Adjuvant|Lung Adenocarcinoma, Stage I|Treatment|Histological Type of Neoplasm
|
September 1, 2017 | Phase 2 |
NCT03564691 | Merck Sharp & Dohme LLC |
Neoplasms
|
July 11, 2018 | Phase 1 |
NCT00191984 | Eli Lilly and Company |
Metastatic Colorectal Cancer
|
June 2004 | Phase 2 |
NCT04736173 | Arcus Biosciences, Inc.|Gilead Sciences |
Non Small Cell Lung Cancer|Nonsquamous Non Small Cell Lung Cancer|Squamous Non-small-cell Lung Cancer|Lung Cancer
|
February 8, 2021 | Phase 3 |
NCT02041533 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Stage IV or Recurrent Non-Small Cell Lung Cancer
|
March 27, 2014 | Phase 3 |
NCT02723578 | Yonsei University |
Metastatic Colorectal Cancer
|
December 1, 2015 | Phase 2 |
NCT04836728 | Tianjin Medical University Cancer Institute and Hospital |
Non-small Cell Lung Cancer Metastatic|First-line Treatment
|
April 1, 2021 | Phase 2 |
NCT00700336 | CanBas Co. Ltd. |
Malignant Pleural Mesothelioma|Solid Tumors
|
May 2008 | Phase 1|Phase 2 |
NCT03762018 | ETOP IBCSG Partners Foundation|Hoffmann-La Roche |
Pleural Mesothelioma Malignant Advanced
|
April 30, 2019 | Phase 3 |
NCT01218516 | Morphotek |
Adenocarcinoma of the Lung
|
June 27, 2011 | Phase 2 |
NCT00315861 | SCRI Development Innovations, LLC|GlaxoSmithKline|Eli Lilly and Company |
Ovarian Cancer|Endometrial Cancer|Cervical Cancer|Lung Cancer
|
March 2006 | Phase 1 |
NCT01471197 | Bristol-Myers Squibb |
Lung Cancer - Non Small Cell
|
July 2012 | Phase 2 |
NCT00268489 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
May 2006 | Phase 2 |
NCT00715611 | Memorial Sloan Kettering Cancer Center|M.D. Anderson Cancer Center|Princess Margaret Hospital, Canada|Mayo Clinic|Brigham and Women´s Hospital |
Mesothelioma
|
October 11, 2008 | Phase 2 |
NCT00380718 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
November 2006 | Phase 4 |
NCT03671538 | Lingyu Luo|The First Affiliated Hospital of Nanchang University |
Non-squamous Non-small Cell Lung Cancer
|
October 1, 2018 | Not Applicable |
NCT02784171 | Canadian Cancer Trials Group|National Cancer Institute, Naples|Merck Sharp & Dohme LLC|Intergroupe Francophone de Cancerologie Thoracique |
Mesothelioma
|
October 7, 2016 | Phase 2|Phase 3 |
NCT05226598 | Merck Sharp & Dohme LLC |
Metastatic Non-Small Cell Lung Cancer
|
March 24, 2022 | Phase 3 |
NCT01373463 | Medical University of South Carolina |
Nonsquamous Nonsmall Cell Neoplasm of Lung|Nonsmall Cell Lung Cancer Stage III
|
May 2011 | Phase 1 |
NCT04177953 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Bristol-Myers Squibb |
Pleural Mesothelioma Malignant
|
February 4, 2019 | Phase 2 |
NCT00129974 | Tufts Medical Center|Eli Lilly and Company |
Carcinoma, Small Cell
|
August 2005 | Phase 2 |
NCT00190918 | Eli Lilly and Company|Gynecologic Oncology Group |
Trophoblastic Neoplasms|Uterine Neoplasms|Hydatidiform Mole|Choriocarcinoma
|
July 2006 | Phase 2 |
NCT00003711 | San Antonio Cancer Institute|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 1997 | Phase 1 |
NCT00386815 | Eli Lilly and Company |
Malignant Pleural Mesothelioma
|
October 2006 | Phase 2 |
NCT04173338 | Augusta University |
Non Small Cell Lung Cancer|Non-squamous Non-small-cell Lung Cancer|Urothelial Carcinoma|Malignant Mesothelioma
|
January 23, 2020 | Phase 1 |
NCT00301808 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lung Cancer
|
November 2005 | Phase 2 |
NCT03190239 | Xinqiao Hospital of Chongqing |
Advanced Non-squamous Non-small-cell Lung Cancer
|
July 15, 2017 | Phase 2 |
NCT05261399 | AstraZeneca |
Carcinoma|Non-Small-Cell Lung
|
August 3, 2022 | Phase 3 |
NCT03498222 | Queen Mary University of London|Polaris Group|Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
June 1, 2018 | Phase 1 |
NCT02453282 | AstraZeneca |
Non-Small-Cell Lung Carcinoma NSCLC
|
July 21, 2015 | Phase 3 |
NCT02922764 | Inspirna, Inc. |
Endometrial Cancer|Endometrial Cancer Recurrent|Lung Cancer Recurrent|Lung Cancer|Non-small Cell Lung Cancer Metastatic|Non-small Cell Carcinoma
|
November 2016 | Phase 1 |
NCT02419495 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma
|
June 26, 2015 | Phase 1 |
NCT05611879 | Beijing Tsinghua Chang Gung Hospital |
NSCLC, Stage III
|
November 1, 2022 | Phase 2 |
NCT03713944 | Nasser Hanna|Genentech, Inc.|Big Ten Cancer Research Consortium |
NSCLC Stage IV|NSCLC, Recurrent
|
November 15, 2018 | Phase 2 |
NCT04956692 | Merck Sharp & Dohme LLC |
Non-Small Cell Lung Cancer
|
August 5, 2021 | Phase 3 |
NCT03138889 | Nektar Therapeutics |
Non-Small Cell Lung Cancer
|
June 9, 2017 | Phase 1|Phase 2 |
NCT00923273 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma, Non-Small-Cell Lung
|
February 29, 2008 | Phase 1|Phase 2 |
NCT02347917 | Sumitomo Pharma Co., Ltd. |
Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer
|
February 2015 | Phase 1|Phase 2 |
NCT02743923 | The Netherlands Cancer Institute|Dutch Society of Physicians for Pulmonology and Tuberculosis |
Carcinoma, Non-Small Cell Lung
|
April 2016 | Phase 3 |
NCT00762034 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
December 2008 | Phase 3 |
NCT03971474 | Southwest Oncology Group|National Cancer Institute (NCI) |
Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
May 28, 2019 | Phase 2 |
NCT00979576 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
October 2009 | Phase 1 |
NCT02804646 | Anhui Provincial Hospital |
Adenocarcinoma of Lung
|
June 2016 | Phase 4 |
NCT05001880 | National Cancer Institute (NCI) |
Peritoneal Malignant Mesothelioma
|
October 15, 2021 | Phase 2 |
NCT02148380 | Baohui Han|Shanghai Chest Hospital |
Non-Small-Cell Lung Cancer
|
May 2014 | Not Applicable |
NCT01454102 | Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
December 16, 2011 | Phase 1 |
NCT02654587 | OSE Immunotherapeutics |
Non Small Cell Lung Cancer
|
February 2016 | Phase 3 |
NCT01918761 | Central European Cooperative Oncology Group |
Non Small Cell Lung Cancer
|
July 30, 2013 | Phase 1 |
NCT00216203 | Nasser Hanna, M.D.|Eli Lilly and Company|Bristol-Myers Squibb|Walther Cancer Institute|Hoosier Cancer Research Network |
Non-Small Cell Lung Cancer
|
May 2005 | Phase 1|Phase 2 |
NCT03655834 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Non Small Cell Lung Cancer|Mesothelioma
|
February 1, 2019 | Phase 4 |
NCT01655225 | Eli Lilly and Company |
Advanced Cancer|Metastatic Cancer|Non-Hodgkin´s Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer
|
July 31, 2012 | Phase 1 |
NCT04538664 | Janssen Research & Development, LLC |
Carcinoma, Non-Small-Cell Lung
|
October 13, 2020 | Phase 3 |
NCT00921310 | Washington University School of Medicine |
Carcinoma, Non-Small-Cell Lung
|
September 2009 | Phase 1|Phase 2 |
NCT00003706 | The University of Texas Health Science Center at San Antonio|Lily Research Laboratories|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 1998 | Phase 1 |
NCT02974933 | Wuling Ou|Jiangsu HengRui Medicine Co., Ltd.|Hubei Clinical Research Collaboration Group|Hubei Cancer Hospital |
Nonsmall Cell Lung Cancer
|
November 2016 | Phase 2 |
NCT00107419 | Southwest Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
September 2005 | Phase 2 |
NCT02578680 | Merck Sharp & Dohme LLC |
Non-Small-Cell Lung Carcinoma
|
January 15, 2016 | Phase 3 |
NCT00738881 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group |
Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
October 2008 | Phase 3 |
NCT00490373 | Eli Lilly and Company |
Pancreatic Cancer
|
October 2003 | Phase 2 |
NCT02919462 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Pierre Fabre Laboratories |
Carcinoma, Non-Small-Cell Lung|Secondary|Advanced Stage IIIB|High Thymidylate Synthase Expression
|
March 2016 | Phase 2 |
NCT04754815 | Shirish Gadgeel|Merck Sharp & Dohme LLC|Henry Ford Health System |
Non Small Cell Lung Cancer|Advanced Lung Non-Small Cell Carcinoma|PD-L1 Gene Mutation
|
April 1, 2021 | Phase 2 |
NCT04316351 | Guangzhou Institute of Respiratory Disease|Shanghai Junshi Bioscience Co., Ltd. |
IIIb+IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
|
April 1, 2020 | Phase 2 |
NCT03952403 | Shanghai Henlius Biotech |
Carcinoma|Non-Small-Cell Lung
|
December 2, 2019 | Phase 3 |
NCT00320515 | Eli Lilly and Company |
Neoplasm, Gastric
|
March 2004 | Phase 1|Phase 2 |
NCT01928160 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
June 2014 | Phase 2 |
NCT05456256 | Lantern Pharma Inc. |
Adenocarcinoma of Lung|Carcinoma, Non-Small-Cell Lung
|
August 12, 2022 | Phase 2 |
NCT04970043 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Lung Cancer Stage II
|
July 31, 2021 | Not Applicable |
NCT00293579 | Ohio State University Comprehensive Cancer Center |
Head and Neck Cancer
|
February 2006 | Phase 2 |
NCT00291707 | University of Pittsburgh|Eli Lilly and Company|Bristol-Myers Squibb |
Head and Neck Cancer
|
March 2006 | Phase 1 |
NCT04153734 | Kobe Minimally Invasive Cancer Center|Merck Sharp & Dohme LLC |
Locally Advanced Non-small Cell Lung Cancer
|
December 1, 2019 | Phase 2 |
NCT00349089 | Thoraxklinik-Heidelberg gGmbH |
Non Small Cell Lung Cancer
|
September 26, 2006 | Phase 2 |
NCT02947113 | The Netherlands Cancer Institute |
Non-Small Cell Lung Cancer
|
November 2017 | Phase 2 |
NCT04765059 | AstraZeneca|Parexel |
Non-small Cell Lung Cancer
|
September 12, 2021 | Phase 3 |
NCT00402766 | M.D. Anderson Cancer Center|Novartis |
Mesothelioma
|
August 2006 | Phase 1 |
NCT01490437 | Asan Medical Center |
Urothelial Carcinoma
|
July 2008 | Phase 2 |
NCT00106002 | Eli Lilly and Company |
Breast Cancer|Breast Neoplasms, Male|Carcinoma, Ductal
|
April 2005 | Phase 2 |
NCT01646125 | Novartis Pharmaceuticals|Novartis |
Advanced Non Small Cell Lung Cancer (NSCLC)
|
November 23, 2012 | Phase 2 |
NCT00424723 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital |
Neuroendocrine Tumors
|
December 2005 | Phase 2 |
NCT03607539 | Innovent Biologics (Suzhou) Co. Ltd. |
Lung Neoplasms
|
August 23, 2018 | Phase 3 |
NCT02274038 | University of Pennsylvania |
Non-small Cell Lung Cancer|Starting Pemetrexed Based Therapy|Unresectable Cancer
|
March 2015 | Not Applicable |
NCT02864251 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Non-Small-Cell Lung Carcinoma
|
March 17, 2017 | Phase 3 |
NCT05153408 | Blueprint Medicines Corporation |
Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Neoplasms|Neoplasms by Site|Lung Diseases|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Nerve Tissue|EGFR C797S|EGFR C797A|EGFR L858R|EGFR Exon 19 Deletion|EGFR Gene Mutation|EGF-R Positive Non-Small Cell Lung Cancer|EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance|EGFR Activating Mutation|Thoracic Neoplasms|Antineoplastic Agents|Protein Kinase Inhibitors|EGFR C797G|EGFR C797X|Non Small Cell Lung Cancer
|
January 13, 2022 | Phase 1|Phase 2 |
NCT05104788 | Peking University Cancer Hospital & Institute |
Non-Small Cell Lung Cancer
|
October 25, 2021 | Phase 2 |
NCT00701857 | University of Arizona|National Cancer Institute (NCI) |
Esophageal Cancer
|
February 2008 | Phase 1 |
NCT04025879 | Bristol-Myers Squibb |
Carcinoma, Non-Small-Cell Lung
|
November 5, 2019 | Phase 3 |
NCT02185690 | University Health Network, Toronto|Novartis Pharmaceuticals |
Lungcancer
|
January 11, 2018 | Phase 1 |
NCT01473563 | Eli Lilly and Company |
Nonsquamous Non-Small Cell Neoplasm of Lung|Non-Small Cell Lung Cancer Metastatic|Non-Small Cell Lung Cancer Stage IIIB
|
December 2011 | Phase 2 |
NCT00604461 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. |
Mesothelioma
|
October 2007 | Phase 1|Phase 2 |
NCT03830411 | Xin-Hua Xu|China Three Gorges University, Yichang, China |
Nonsquamous Non-Small Cell Lung Cancer
|
March 13, 2019 | Phase 2 |
NCT00577707 | Memorial Sloan Kettering Cancer Center|Genentech, Inc. |
Non Small Cell Lung Cancer|Lung Cancer
|
November 2007 | Phase 2 |
NCT00732303 | Hoosier Cancer Research Network|Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
January 2009 | Phase 2 |
NCT04895735 | Mayo Clinic|National Cancer Institute (NCI) |
Metastatic Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8
|
July 23, 2021 | Phase 2 |
NCT03944772 | AstraZeneca |
Non-Small Cell Lung Cancer
|
June 25, 2019 | Phase 2 |
NCT00280748 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer|Metastatic Cancer
|
May 2005 | Phase 2 |
NCT00410904 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer
|
October 2006 | Phase 2 |
NCT05273814 | Tianjin Medical University Cancer Institute and Hospital |
Non-Small Cell Lung Cancer
|
August 1, 2022 | Phase 1 |
NCT00034489 | Eli Lilly and Company |
Breast Neoplasms
|
Phase 2 | |
NCT00418886 | Genzyme, a Sanofi Company|Sanofi |
Non Small Cell Lung Cancer|Lung Cancer
|
January 2007 | Phase 3 |
NCT04592666 | Fudan University |
Lung Cancer, Non-small Cell|EGFR T790M|EGFR Gene Mutation
|
October 9, 2020 | Phase 2 |
NCT02124148 | Eli Lilly and Company |
Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer
|
June 18, 2014 | Phase 1 |
NCT03792503 | Xinqiao Hospital of Chongqing |
Advanced Non-squamous Non-small-cell Lung Cancer
|
February 2019 | Phase 4 |
NCT04837716 | M.D. Anderson Cancer Center |
Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
March 18, 2021 | Phase 1 |
NCT00365183 | Pharmacyclics LLC. |
Non-Small Cell Lung Carcinoma
|
June 2006 | Phase 2 |
NCT05298423 | Merck Sharp & Dohme LLC |
Carcinoma, Non-Small-Cell Lung
|
May 3, 2022 | Phase 3 |
NCT00203931 | University of Chicago|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
March 2005 | Phase 2 |
NCT02868892 | Western Regional Medical Center |
Adenocarcinoma of the Cervix|Adenosquamous Cell Carcinoma of the Cervix
|
July 2015 | Phase 2 |
NCT00409006 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
February 2007 | Phase 2 |
NCT03778138 | Henan Provincial People´s Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Non-squamous Cell Non-Small Cell Lung Cancer
|
January 1, 2019 | Phase 2 |
NCT05136677 | Bristol-Myers Squibb |
Mesothelioma, Malignant
|
January 25, 2022 | Phase 2 |
NCT02337530 | Canadian Cancer Trials Group|AstraZeneca |
Non-Small Cell Lung Cancer
|
February 5, 2015 | Phase 2 |
NCT00059865 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer
|
January 2004 | Phase 1|Phase 2 |
NCT02004184 | Norwegian University of Science and Technology|St. Olavs Hospital |
Carcinoma, Non-small-cell Lung
|
December 2013 | Phase 3 |
NCT04500704 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Non Small Cell Lung Cancer
|
October 2020 | Phase 3 |
NCT00190762 | Eli Lilly and Company |
Mesothelioma
|
October 2001 | Phase 3 |
NCT02951637 | Shanghai Chest Hospital|Ruijin Hospital|Changhai Hospital |
Lung Adenocarcinoma
|
December 2016 | Phase 2 |
NCT02576574 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
First Line Non-Small Cell Lung Cancer
|
October 29, 2015 | Phase 3 |
NCT00903292 | National Cheng-Kung University Hospital |
Non-Small Cell Lung Cancer
|
March 2009 | Not Applicable |
NCT02588781 | Samsung Medical Center |
Colorectal Cancer
|
October 2015 | Phase 2 |
NCT00786331 | Gruppo Oncologico Italiano di Ricerca Clinica |
Advanced Non-Small Cell Lung Cancer
|
July 2007 | Phase 2 |
NCT01172470 | University of Chicago |
Head and Neck Cancer
|
June 2005 | Phase 2 |
NCT01502202 | National Cancer Center, Korea|AstraZeneca |
Non Small Cell Lung Cancer|Adenocarcinoma
|
March 2012 | Phase 2 |
NCT05132413 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
|
December 30, 2021 | Phase 3 |
NCT03058094 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
NSCLC
|
December 2018 | Phase 3 |
NCT05244837 | Hao Long|Sun Yat-sen University |
Tislelizumab|Safety|Biomarker|Chemotherapy
|
December 22, 2020 | Phase 2 |
NCT03544814 | Shanghai Chest Hospital |
Lung Adenocarcinoma|EGFR Activating Mutation
|
January 1, 2015 | Phase 2 |
NCT04500717 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Non Small Cell Lung Cancer
|
October 2020 | Phase 3 |
NCT04410796 | Memorial Sloan Kettering Cancer Center|AstraZeneca|GUARDANT HEALTH |
Metastatic Non-small Cell Lung Cancer
|
May 28, 2020 | Phase 2 |
NCT00330915 | Eli Lilly and Company |
Rectal Neoplasms
|
June 2006 | Phase 2 |
NCT00942825 | CanBas Co. Ltd. |
Metastatic Non-squamous Non Small Cell Lung Cancer
|
April 2009 | Phase 2 |
NCT03991403 | Samsung Medical Center |
Non-small Cell Lung Cancer
|
August 27, 2019 | Phase 3 |
NCT00387322 | University of California, Davis|National Cancer Institute (NCI) |
Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 2005 | Phase 1|Phase 2 |
NCT05459441 | Shanghai Pudong Hospital |
Glioma|Brain Metastases
|
January 1, 2022 | Early Phase 1 |
NCT04647344 | Akeso |
Lung Cancer Non-Small Cell Stage IIIB+IIIC+IV
|
November 24, 2020 | Phase 1|Phase 2 |
NCT00356525 | Eli Lilly and Company |
Lung Neoplasms
|
September 2006 | Phase 2 |
NCT00415168 | Eli Lilly and Company |
Gastric Cancer
|
December 2006 | Phase 2 |
NCT04136535 | Fudan University |
NSCLC Stage IV
|
October 18, 2019 | Phase 2 |
NCT03829319 | Merck Sharp & Dohme LLC|Eisai Inc. |
Nonsquamous Non-small Cell Lung Cancer
|
March 25, 2019 | Phase 3 |
NCT01553942 | Massachusetts General Hospital |
Lung Cancer
|
April 2012 | Phase 2 |
NCT04524689 | Sanofi |
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
|
October 26, 2020 | Phase 2 |
NCT01569919 | Wales Cancer Trials Unit|Velindre NHS Trust|June Hancock Mesothelioma Research Fund|Velindre Cancer Centre Stepping Stones Appeal |
Malignant|Pleural|Mesothelioma
|
December 2012 | Phase 2 |
NCT01700400 | Cancer Research and Biostatistics Clinical Trials Consortium|University of Arizona|Providence Cancer Center, Earle A. Chiles Research Institute|Novartis Pharmaceuticals |
Non Small Cell Lung Cancer
|
September 2012 | Phase 1 |
NCT02595840 | Universität Duisburg-Essen |
Non-small-cell Lung Cancer With Somatic EGFR Mutations
|
November 25, 2015 | Phase 2 |
NCT00489359 | Eli Lilly and Company |
Ovarian Cancer|Primary Peritoneal Cancer
|
July 2005 | Phase 1|Phase 2 |
NCT03061058 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Stomach Neoplasms|Chemotherapy Effect|Chemotherapeutic Toxicity
|
April 1, 2013 | Phase 3 |
NCT00494026 | Eli Lilly and Company |
Small Cell Lung Cancer
|
September 2007 | Phase 2 |
NCT04991025 | Memorial Sloan Kettering Cancer Center |
Lung Cancer|Lung Cancer Stage II|Lung Cancer Stage III
|
October 19, 2022 | Phase 2 |
NCT04439890 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Advanced Non-squamous Cell Non-small Cell Lung Cancer
|
August 8, 2019 | Phase 3 |
NCT04203485 | Jiangsu HengRui Medicine Co., Ltd. |
PD-L1 Positive Non-small Cell Lung Cancer
|
June 15, 2020 | Phase 3 |
NCT02407366 | People´s Hospital of Guangxi |
Non-small Cell Lung Cancer
|
December 2014 | Phase 2 |
NCT01836341 | Memorial Sloan Kettering Cancer Center|Boehringer Ingelheim|National Comprehensive Cancer Network |
Non-small Cell Lung Cancer
|
April 2013 | Phase 1 |
NCT00374868 | Eli Lilly and Company |
Urologic Neoplasms
|
August 2006 | Phase 1|Phase 2 |
NCT03242915 | University of Michigan Rogel Cancer Center |
Non-small Cell Lung Cancer
|
October 3, 2017 | Phase 2 |
NCT03875144 | Institut du Cancer de Montpellier - Val d´Aurelle |
Peritoneal Mesothelioma|Peritoneal Carcinomatosis
|
August 14, 2020 | Phase 2 |
NCT00065533 | Eli Lilly and Company |
Breast Cancer
|
May 2003 | Phase 2 |
NCT03850444 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
August 1, 2016 | Phase 3 |
NCT03574402 | Guangdong Association of Clinical Trials|Chinese Thoracic Oncology Group |
Carcinoma, Non-Small-Cell Lung
|
July 9, 2018 | Phase 2 |
NCT00741221 | Hellenic Oncology Research Group |
Non-small-cell Lung Cancer
|
June 2008 | Phase 2 |
NCT01784640 | Jonsson Comprehensive Cancer Center|Translational Research in Oncology|Novartis |
Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
January 31, 2014 | Phase 1 |
NCT04164199 | BeiGene |
Advanced Malignancies
|
December 19, 2019 | Phase 3 |
NCT02259582 | OncoMed Pharmaceuticals, Inc.|Celgene Corporation|Mereo BioPharma |
Nonsquamous Nonsmall Cell Neoplasm of Lung
|
February 2015 | Phase 2 |
NCT02409342 | Hoffmann-La Roche |
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
|
July 20, 2015 | Phase 3 |
NCT01209520 | University of Miami |
Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation
|
July 2009 | Not Applicable |
NCT03380468 | Fudan University |
Lung Neoplasms
|
January 1, 2018 | Phase 2|Phase 3 |
NCT01004601 | Chang Gung Memorial Hospital |
Non Small Cell Lung Cancer
|
March 2005 | Not Applicable |
NCT03158129 | M.D. Anderson Cancer Center |
Stage I Lung Non-Small Cell Cancer AJCC v7|Stage IA Lung Non-Small Cell Carcinoma AJCC v7|Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7
|
June 9, 2017 | Phase 2 |
NCT04253964 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Nonsmall Cell Lung Cancer|Performance Status
|
July 1, 2020 | Phase 2 |
NCT01544179 | AstraZeneca |
Non-Small Cell Lung Cancer
|
March 15, 2012 | Phase 3 |
NCT00427466 | University Hospital Tuebingen|Arbeitsgemeinschaft fur Internistische Onkologie|German Sarcoma Group |
Sarcoma
|
January 2007 | Phase 2 |
NCT02031601 | Qilu Hospital of Shandong University |
Non-Small-Cell Lung Cancer
|
January 2014 | Phase 4 |
NCT00191412 | Eli Lilly and Company |
Liver Cancer
|
January 2005 | Phase 2 |
NCT05118854 | M.D. Anderson Cancer Center|Amgen |
Lung Cancer
|
March 30, 2022 | Phase 2 |
NCT05255302 | Intergroupe Francophone de Cancerologie Thoracique |
Metastatic NSCLC
|
May 2, 2022 | Phase 2|Phase 3 |
NCT05403385 | iTeos Belgium SA|iTeos Therapeutics |
Metastatic NSCLC|Stage III NSCLC
|
August 26, 2022 | Phase 2 |
NCT00541073 | Centre Oscar Lambret|National Cancer Institute (NCI) |
Malignant Mesothelioma
|
June 2007 | Phase 2 |
NCT05011487 | Sun Yat-sen University |
Non-Small Cell Lung Cancer
|
August 13, 2021 | Phase 2 |
NCT03233139 | Regeneron Pharmaceuticals |
Advanced Malignancies
|
June 21, 2017 | Phase 1 |
NCT00087698 | Eli Lilly and Company |
Pleural Neoplasms
|
September 2003 | Phase 2 |
NCT03655821 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Non Small Cell Lung Cancer|Mesothelioma
|
February 1, 2019 | Phase 4 |
NCT05258279 | Juntendo University|Merck Sharp & Dohme LLC |
Non-squamous Non-small-cell Lung Cancer|EGFR Activating Mutation
|
July 2022 | Phase 2 |
NCT01631136 | Intergroupe Francophone de Cancerologie Thoracique|Groupe Francais De Pneumo-Cancerologie |
Advanced Non Small Cell Lung Cancer
|
July 2012 | Phase 3 |
NCT04245085 | ETOP IBCSG Partners Foundation|Roche Pharma AG |
EGFRmutant Stage IIIB+C or IV Non-squamous NSCLC
|
September 29, 2020 | Phase 2 |
NCT00698815 | National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7
|
April 15, 2008 | Phase 2 |
NCT00372788 | AstraZeneca |
Non-small Cell Lung Cancer
|
August 2006 | Phase 2 |
NCT04943627 | Agenus Inc.|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Advanced Cancer|Metastatic Cervical Cancer
|
August 2, 2021 | Phase 3 |
NCT00509366 | Duke University|Eli Lilly and Company |
Non Small Cell Lung Cancer
|
May 2007 | Phase 2 |
NCT05555732 | Daiichi Sankyo, Inc.|AstraZeneca|Merck Sharp & Dohme LLC |
Metastatic Non Small Cell Lung Cancer
|
November 2022 | Phase 3 |
NCT00540241 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
September 2007 | |
NCT02488694 | AIO-Studien-gGmbH|Boehringer Ingelheim |
Non-small-cell Lung Cancer With Somatic EGFR Mutations
|
November 2015 | Phase 2 |
NCT01708993 | Canadian Cancer Trials Group|Oncolytics Biotech |
Non Small Cell Lung Cancer
|
October 15, 2012 | Phase 2 |
NCT00101283 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group |
Mesothelioma
|
November 2005 | Phase 2 |
NCT00383331 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
February 2007 | Phase 2 |
NCT04638582 | McGill University Health Centre+Research Institute of the McGill University Health Centre |
Lung Cancer, Nonsmall Cell
|
June 2021 | Phase 2 |
NCT05096663 | Southwest Oncology Group|National Cancer Institute (NCI) |
Advanced Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
February 15, 2022 | Phase 2|Phase 3 |
NCT05015608 | Hutchison Medipharma Limited|Hutchmed |
Non-small Cell Lung Cancer
|
November 22, 2021 | Phase 3 |
NCT00350792 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
August 2006 | Phase 2 |
NCT05394233 | Sichuan Cancer Hospital and Research Institute |
Non-squamous Non-small Cell Lung Cancer|EGFR Gene Mutation
|
June 1, 2022 | Phase 2 |
NCT04165070 | Merck Sharp & Dohme LLC |
Carcinoma, Non-Small-Cell Lung
|
December 19, 2019 | Phase 2 |
NCT00369629 | Northwestern University|National Cancer Institute (NCI)|Eli Lilly and Company |
Lymphoma
|
August 28, 2006 | Phase 1 |
NCT03770299 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA
|
January 15, 2021 | Phase 2 |
NCT02657434 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
April 30, 2016 | Phase 3 |
NCT05253118 | Seoul National University Hospital|Seoul National University Bundang Hospital |
DLBCL
|
August 18, 2022 | Phase 2 |
NCT04832854 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer (NSCLC)
|
April 23, 2021 | Phase 2 |
NCT04455594 | The First Affiliated Hospital of Guangzhou Medical University |
Non-Small Cell Lung Cancer Stage IIIA
|
October 2020 | Phase 2 |
NCT04750083 | Taizhou Hanzhong biomedical co. LTD |
Nonsquamous Non-small Cell Lung Cancer
|
September 25, 2020 | Phase 2|Phase 3 |
NCT02930954 | Caicun Zhou|Tongji University |
Non-small-cell Lung Cancer
|
November 2016 | Phase 2 |
NCT00190671 | Eli Lilly and Company |
Breast Cancer
|
June 2005 | Phase 1|Phase 2 |
NCT03636685 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
NSCLC|Adenocarcinoma|Squamous Cell Carcinoma
|
August 15, 2018 | Phase 1|Phase 2 |
NCT02631460 | Sun Yat-sen University |
NSCLC
|
December 2015 | Phase 2 |
NCT05502237 | Gilead Sciences|Arcus Biosciences, Inc. |
Non-small Cell Lung Cancer
|
October 12, 2022 | Phase 3 |
NCT00101842 | Eli Lilly and Company |
Carcinoma, Transitional Cell
|
December 2004 | Phase 1|Phase 2 |
NCT04622007 | Effector Therapeutics|Medpace, Inc. |
Non-small Cell Lung Cancer
|
June 2, 2021 | Phase 2 |
NCT03319537 | Memorial Sloan Kettering Cancer Center|M.D. Anderson Cancer Center |
Mesothelioma
|
October 5, 2017 | Phase 1|Phase 2 |
NCT00106626 | Merck Sharp & Dohme LLC |
Advanced Cancer
|
August 2005 | Phase 1 |
NCT04351555 | AstraZeneca |
Non-Small Cell Lung Cancer
|
December 16, 2020 | Phase 3 |
NCT01282151 | Chonnam National University Hospital|Sanofi |
Carcinoma, Non Small Cell Lung
|
July 2011 | Phase 3 |
NCT01565538 | Si-Yu Wang|Sun Yat-sen University |
Lung Cancer
|
December 2008 | Phase 2 |
NCT00520845 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
October 2007 | Phase 2 |
NCT00619424 | GlaxoSmithKline |
Lung Cancer, Non-Small Cell
|
November 15, 2007 | Phase 1 |
NCT02862457 | Merck Sharp & Dohme LLC |
Neoplasms|Carcinoma, Non-Small-Cell Lung
|
August 23, 2016 | Phase 1 |
NCT01303926 | Gruppo Oncologico Italia Meridionale |
Non-squamous Nonsmall Cell Neoplasm of Lung
|
January 2010 | Phase 3 |
NCT03003962 | AstraZeneca |
Non Small Cell Lung Carcinoma NSCLC
|
January 2, 2017 | Phase 3 |
NCT05386888 | Genfleet Therapeutics (Shanghai) Inc. |
NSCLC, Stage III
|
September 1, 2022 | Phase 2 |
NCT01578668 | Guangzhou Medical University |
Lung Adenocarcinoma|Brain Metastases
|
January 2012 | Phase 2 |
NCT02693717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Urothelial Carcinoma
|
May 9, 2017 | Phase 2 |
NCT00434174 | Novartis Pharmaceuticals|Novartis |
Non Small Cell Lung Cancer
|
December 2006 | Phase 1 |
NCT04507217 | Sun Yat-sen University |
NSCLC Stage IV|Brain Metastases|PD-1 Antibody
|
September 1, 2020 | Phase 2 |
NCT03432598 | BeiGene |
Locally Advanced Lung Cancer; Metastatic Lung Cancer
|
August 24, 2017 | Phase 2 |
NCT00538681 | Eli Lilly and Company |
Lung Cancer
|
September 2007 | Phase 2 |
NCT02087241 | AstraZeneca |
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
|
March 2014 | Phase 2 |
NCT00389805 | University of California, Davis|Eli Lilly and Company |
Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 2005 | Phase 1|Phase 2 |
NCT00867009 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
April 2009 | Phase 2 |
NCT04453423 | The First Affiliated Hospital with Nanjing Medical University |
Non-squamous Non-small-cell Lung Cancer
|
July 1, 2020 | Phase 2 |
NCT03515837 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
June 29, 2018 | Phase 3 |
NCT03086538 | Samsung Medical Center |
Colo-rectal Cancer
|
May 30, 2017 | Phase 2 |
NCT05501665 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Varian Medical Systems |
Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8
|
January 31, 2023 | Phase 1|Phase 2 |
NCT03744793 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation|Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Urothelial Carcinoma|MTAP Negative
|
April 11, 2019 | Phase 2 |
NCT04205812 | Incyte Corporation|Zai Lab (Shanghai) Co., Ltd. |
Metastatic Squamous Non-Small Cell Lung Cancer|Metastatic Nonsquamous Non-Small Cell Lung Cancer
|
September 27, 2020 | Phase 3 |
NCT02838745 | Baylor College of Medicine |
Mesothelioma
|
September 2016 | Phase 1 |
NCT03064854 | Novartis Pharmaceuticals|Novartis |
Non-small Cell Lung Cancer
|
May 24, 2017 | Phase 1 |
NCT01454934 | Eisai Inc. |
Non-Small Cell Lung Cancer (NSCLC)
|
December 9, 2011 | Phase 3 |
NCT00390000 | Mayo Clinic|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
January 25, 2007 | Phase 1 |
NCT00316225 | Eli Lilly and Company |
Non-small Cell Lung Cancer|Mesothelioma|Lung Neoplasms
|
December 2006 | Phase 2 |
NCT01828099 | Novartis Pharmaceuticals|Novartis |
Non-Small Cell Lung Cancer
|
July 9, 2013 | Phase 3 |
NCT01664754 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage IV Non-small Cell Lung Cancer
|
September 7, 2012 | Phase 1 |
NCT01469000 | Eli Lilly and Company |
Carcinoma, Non Small Cell Lung
|
February 2012 | Phase 2 |
NCT03664024 | Merck Sharp & Dohme LLC |
Non-Small Cell Lung Cancer
|
October 30, 2018 | Phase 2 |
NCT02399566 | Hunan Province Tumor Hospital |
Lung Adenocarcinoma
|
May 2015 | Phase 4 |
NCT04966663 | University Health Network, Toronto|Bristol-Myers Squibb |
Non Small Cell Lung Cancer|Complete Surgical Resection|Circulating Tumor DNA
|
March 28, 2022 | Phase 2 |
NCT02518802 | Tang-Du Hospital |
Lung Neoplasms
|
January 2015 | Phase 3 |
NCT01836575 | Instituto Nacional de Cancer, Brazil|Eli Lilly and Company |
Non Small Cell Lung Carcinoma
|
April 2008 | Phase 3 |
NCT01909830 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Colorectal Cancer Metastatic
|
July 2012 | Phase 2 |
NCT03402048 | University of Turin, Italy |
Stage IV, NSCLC|Lung Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Lung Diseases|Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Thoracic Neoplasms
|
July 2012 | Phase 3 |
NCT04367311 | Nasser Hanna|Genentech, Inc.|Big Ten Cancer Research Consortium |
Lung Cancer|NSCLC
|
May 22, 2020 | Phase 2 |
NCT00871403 | GlaxoSmithKline |
Lung Cancer, Non-Small Cell
|
July 2009 | Phase 2 |
NCT00061477 | Eli Lilly and Company |
Mesothelioma
|
December 2002 | Phase 2 |
NCT03509012 | AstraZeneca |
Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Non-Small-Cell Lung|Small Cell Lung Carcinoma
|
May 2, 2018 | Phase 1 |
NCT03337698 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
January 2, 2018 | Phase 1|Phase 2 |
NCT00961415 | Hoffmann-La Roche |
Non-Squamous Non-Small Cell Lung Cancer
|
August 2009 | Phase 3 |
NCT00835471 | Dutch Society of Physicians for Pulmonology and Tuberculosis |
Carcinoma, Non-Small-Cell Lung
|
March 2009 | Phase 2 |
NCT04623775 | Bristol-Myers Squibb |
Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer
|
February 17, 2021 | Phase 2 |
NCT03177291 | H. Lee Moffitt Cancer Center and Research Institute |
Lung Cancer|Non Small Cell Lung Cancer|Advanced Cancer|Metastatic Lung Cancer|Squamous Cell Lung Cancer|Non-Squamous Non-Small Cell Neoplasm of Lung
|
September 26, 2017 | Phase 1 |
NCT00061464 | Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung
|
February 2003 | Phase 2 |
NCT04706949 | Fudan University |
Lung Cancer, Non-small Cell
|
December 7, 2020 | Phase 2 |
NCT01445392 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Mesothelioma
|
November 14, 2007 | Phase 1 |
NCT03396445 | Merck Sharp & Dohme LLC |
Pharmacokinetics|Solid Tumor|Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Neoplasms
|
February 18, 2018 | Phase 1 |
NCT00269152 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
December 2005 | Phase 2 |
NCT05469178 | BerGenBio ASA |
Carcinoma, Non-Small-Cell Lung
|
October 2022 | Phase 1|Phase 2 |
NCT00078260 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
December 2003 | Phase 3 |
NCT00887549 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
April 2009 | Phase 2 |
NCT03193788 | Asan Medical Center|Korean Cancer Study Group |
Bladder Cancer|Ureter Cancer|Transitional Cell Carcinoma
|
January 2017 | Phase 3 |
NCT02142738 | Merck Sharp & Dohme LLC |
Non-Small Cell Lung Carcinoma
|
August 25, 2014 | Phase 3 |
NCT00988858 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2009 | Phase 2 |
NCT04211090 | Sun Yat-sen University|Jiangsu HengRui Medicine Co., Ltd. |
Non-squamous Non-small-cell Lung Cancer|Brain Metastases
|
January 15, 2020 | Phase 2 |
NCT01004250 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
October 2009 | Phase 2 |
NCT01723800 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
July 2013 | Phase 1 |
NCT02607423 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Stage IIIA Non-Small Cell Lung Cancer
|
November 19, 2015 | Phase 2 |
NCT03269162 | lihegen|Shanghai University of Traditional Chinese Medicine |
NSCLC
|
September 30, 2016 | Phase 3 |
NCT02037997 | Fudan University |
Non Small Cell Lung Cancer
|
December 2013 | Phase 2 |
NCT01868022 | GlaxoSmithKline |
Neoplasms
|
October 9, 2013 | Phase 1 |
NCT03631784 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
October 19, 2018 | Phase 2 |
NCT01109615 | Vejle Hospital |
Metastatic Colorectal Cancer
|
April 2010 | Phase 2 |
NCT00095199 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
January 2005 | Phase 3 |
NCT03023319 | Nagla Abdel Karim|Augusta University |
Carcinoma, Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical Cancer
|
December 10, 2019 | Phase 1 |
NCT00799240 | University of Kansas|Merck Sharp & Dohme LLC|University of Kansas Medical Center |
Non Small Cell Lung Cancer
|
June 2009 | Phase 2 |
NCT01397305 | Isofol Medical AB |
Rectal Cancer
|
April 14, 2011 | Phase 1|Phase 2 |
NCT02296671 | Washington University School of Medicine|Gateway for Cancer Research |
Esophagogastric Cancer
|
February 2015 | Phase 2 |
NCT01057589 | Eli Lilly and Company |
Head and Neck Neoplasms
|
February 2010 | Phase 2 |
NCT04697628 | Seagen Inc.|Genmab |
Cervical Cancer
|
February 22, 2021 | Phase 3 |
NCT01063283 | University of Chicago|Genentech, Inc. |
Advanced Non-squamous Non-Small Cell Lung Cancer
|
March 2010 | Not Applicable |
NCT02220894 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
October 30, 2014 | Phase 3 |
NCT05281406 | Goethe University |
NSCLC Stage IIIB|NSCLC Stage IV
|
November 12, 2021 | Phase 2 |
NCT05047250 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
June 15, 2022 | Phase 3 |
NCT00149214 | Eli Lilly and Company |
Breast Cancer
|
September 2005 | Phase 2 |
NCT02264990 | AbbVie |
Non-squamous Non-small Cell Lung Cancer
|
September 30, 2014 | Phase 3 |
NCT01907100 | Boehringer Ingelheim |
Mesothelioma
|
September 19, 2013 | Phase 2|Phase 3 |
NCT04452214 | Cantargia AB |
Carcinoma, Non-Small-Cell Lung|Urothelial Carcinoma|Malignant Melanoma|Head and Neck Squamous Cell Carcinoma
|
September 24, 2020 | Phase 1 |
NCT01783834 | Gachon University Gil Medical Center |
Previous Treated Metastatic Non-small Cell Lung Cancer
|
February 2008 | Phase 2 |
NCT00702299 | University of Arizona|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
September 2007 | Phase 1 |
NCT01087970 | Eli Lilly and Company |
Head and Neck Neoplasms
|
August 2010 | Phase 2 |
NCT01263782 | M.D. Anderson Cancer Center|Eli Lilly and Company|Genentech, Inc. |
Lung Cancer
|
May 17, 2011 | Phase 2 |
NCT05527808 | Jun Liu|Guangzhou Institute of Respiratory Disease |
Non Small Cell Lung Cancer
|
August 1, 2022 | Not Applicable |
NCT01809210 | AstraZeneca |
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
|
April 4, 2013 | Phase 1 |
NCT00974584 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
October 2009 | Phase 1 |
NCT01828112 | Novartis Pharmaceuticals|Novartis |
Non-Small Cell Lung Cancer
|
June 28, 2013 | Phase 3 |
NCT00216216 | Hoosier Cancer Research Network|Eli Lilly and Company|Walther Cancer Institute |
Small Cell Lung Cancer
|
January 2005 | Phase 2 |
NCT04971187 | M.D. Anderson Cancer Center |
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
|
June 30, 2021 | Phase 2 |
NCT01287520 | Eli Lilly and Company |
Advanced Cancer
|
November 2007 | Phase 1 |
NCT00072865 | Eli Lilly and Company |
Breast Cancer|Neoplasm Metastasis
|
June 2003 | Phase 2 |
NCT00259285 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
November 2005 | Phase 2 |
NCT00786552 | University Hospital Schleswig-Holstein |
Thyroid Cancer
|
November 2008 | Phase 2 |
NCT01878617 | St. Jude Children´s Research Hospital|Genentech, Inc.|National Cancer Institute (NCI) |
Medulloblastoma
|
June 23, 2013 | Phase 2 |
NCT03041181 | Nasser Hanna, M.D.|Hoosier Cancer Research Network|Bristol-Myers Squibb |
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Adenocarcinoma of the Lung|Lung Cancer|Squamous Cell Lung Cancer
|
January 27, 2017 | Phase 2 |
NCT00609518 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
February 2008 | Phase 2 |
NCT03215706 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
August 24, 2017 | Phase 3 |
NCT04988295 | Janssen Research & Development, LLC |
Carcinoma, Non-Small-Cell Lung
|
November 17, 2021 | Phase 3 |
NCT05289908 | The First Hospital of Jilin University|The Affiliated Hospital of Guangdong Medical College|Second Affiliated Hospital of Guangzhou Medical University|Guangdong 999 Brain Hospital|The Second Hospital of Hebei Medical University|Panjin Liaoyou Gem Flower Hospital|Wuxi People´s Hospital|Huizhou Third People´s Hospital, Guangzhou Medical University |
Leptomeningeal Metastases
|
February 21, 2022 | Phase 1|Phase 2 |
NCT02669719 | Shanghai Chest Hospital|SOTIO a.s. |
Non Small Cell Lung Cancer
|
January 2016 | Phase 2 |
NCT00475657 | Eli Lilly and Company |
Small Cell Lung Cancer
|
October 2007 | Phase 2 |
NCT02367781 | Hoffmann-La Roche |
Carcinoma, Non-Squamous Non-Small Cell Lung
|
April 16, 2015 | Phase 3 |
NCT01344824 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
March 2010 | Phase 2 |
NCT01165021 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2010 | Phase 2 |
NCT03912389 | Biocad |
Non-Squamous Non-Small Cell Neoplasm of Lung
|
June 1, 2019 | Phase 3 |
NCT02486718 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
October 31, 2015 | Phase 3 |
NCT04794699 | IDEAYA Biosciences |
Solid Tumor
|
April 14, 2021 | Phase 1 |
NCT04194203 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
April 9, 2020 | Phase 3 |
NCT03777124 | Jiangsu HengRui Medicine Co., Ltd.|Shanghai Chest Hospital |
NSCLC Stage IV|KRAS Gene Mutation|PD-1 Antibody|Chemotherapy Effect
|
February 2019 | Phase 2 |
NCT00310050 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Pancreatic Cancer
|
October 2005 | Phase 1 |
NCT03256136 | Massachusetts General Hospital|Bristol-Myers Squibb |
Lung Cancer
|
November 22, 2017 | Phase 2 |
NCT00295503 | University of Texas Southwestern Medical Center|University of Chicago|Columbia University|Duke University |
Mesothelioma
|
February 2006 | Phase 2 |
NCT05017012 | Merck Sharp & Dohme LLC |
Advanced or Metastatic Solid Tumors
|
September 21, 2021 | Phase 1 |
NCT03843853 | The First Affiliated Hospital with Nanjing Medical University|Jiangsu HanSoh Tharmaceutical Group Co., Ltd |
Colorectal Neoplasms
|
May 1, 2019 | Phase 2 |
NCT01085630 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Malignant Mesothelioma
|
April 2010 | Phase 2 |
NCT03760575 | Abramson Cancer Center of the University of Pennsylvania |
Mesotheliomas Pleural
|
October 28, 2022 | Phase 1 |
NCT01353482 | University College, London|Merck Sharp & Dohme LLC |
Malignant Pleural Mesothelioma
|
Phase 1|Phase 2 | |
NCT02001168 | Xinjiang Medical University |
Non-small Cell Lung Cancer
|
October 2013 | Phase 3 |
NCT01126736 | Eisai Inc.|Quintiles, Inc. |
Non Small Cell Lung Cancer
|
June 10, 2010 | Phase 1|Phase 2 |
NCT04328844 | iOnctura |
Solid Tumor, Adult|Non-Hodgkin Lymphoma, Adult|NSCLC|Myelofibrosis|Uveal Melanoma
|
February 25, 2020 | Phase 1 |
NCT03920839 | Incyte Corporation |
Advanced and+or Metastatic Solid Tumors|Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer|Advanced+Metastatic Unresectable Malignant Pleural Mesothelioma
|
July 15, 2019 | Phase 1 |
NCT04683965 | The First Affiliated Hospital with Nanjing Medical University|Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Colorectal Neoplasms
|
January 1, 2021 | Phase 2 |
NCT03242616 | Seoul National University Hospital |
Breast Neoplasms
|
February 17, 2017 | Phase 2 |
NCT00248495 | Roswell Park Cancer Institute |
Lung Cancer
|
June 8, 2005 | Phase 2 |
NCT00053209 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
April 2004 | Phase 2 |
NCT03164694 | Sun Yat-sen University |
Lung Cancer
|
May 20, 2017 | Phase 2 |
NCT02568033 | The Cooper Health System |
Non Small Cell Lung Cancer
|
October 2013 | Early Phase 1 |
NCT05487391 | Qilu Pharmaceutical Co., Ltd. |
Carcinoma, Non-Small-Cell Lung
|
October 1, 2022 | Phase 3 |
NCT00351039 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc.|Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
July 2006 | Phase 1|Phase 2 |
NCT00230542 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer
|
September 2005 | Phase 2 |
NCT04162015 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb |
Malignant Pleural Mesothelioma
|
November 12, 2019 | Phase 1 |
NCT04153565 | Merck Sharp & Dohme LLC |
Mesothelioma
|
December 9, 2019 | Phase 1 |
NCT00824408 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
March 2009 | Phase 2 |
NCT00061451 | Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung
|
December 2002 | Phase 2 |
NCT04964960 | John L. Villano, MD, PhD|University of Kentucky |
Lung Cancer|Lung Cancer Metastatic|Brain Cancer|Cancer
|
December 7, 2021 | Phase 2 |
NCT00415194 | Eli Lilly and Company |
Head and Neck Neoplasms
|
December 2006 | Phase 3 |
NCT00630149 | Sun Yat-sen University|Eli Lilly and Company |
Nasopharyngeal Neoplasms
|
November 2007 | Phase 2 |
NCT03559049 | University of Michigan Rogel Cancer Center|Merck Sharp & Dohme LLC|Clovis Oncology, Inc. |
Stage IV Non-small Cell Lung Cancer
|
December 24, 2018 | Phase 1|Phase 2 |
NCT02039674 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Carcinoma
|
February 21, 2014 | Phase 1|Phase 2 |
NCT01531790 | Jiangsu Simcere Pharmaceutical Co., Ltd. |
Non-Small Cell Lung Cancer
|
September 2011 | Phase 1 |
NCT01993810 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7
|
February 3, 2014 | Phase 3 |
NCT03863483 | Xin-Hua Xu|China Three Gorges University, Yichang, China |
Nonsquamous Non-Small Cell Lung Cancer
|
March 26, 2019 | Phase 2 |
NCT03790228 | Henan Cancer Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Non-squamous Cell Non-Small Cell Lung Cancer
|
March 22, 2019 | Phase 1 |
NCT02013453 | University of Michigan Rogel Cancer Center |
Cancer of Head and Neck
|
December 2013 | Phase 2 |
NCT03709147 | Marina Garassino|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Advanced LKB1-inactive Lung Adenocarcinoma
|
October 30, 2018 | Phase 2 |
NCT04470674 | Shirish M Gadgeel|AstraZeneca|Henry Ford Health System|Hoosier Cancer Research Network |
Lung Cancer|Non-small Cell Lung Cancer|PD-L1 Gene Mutation|KRAS Activating Mutation
|
April 6, 2021 | Phase 2 |
NCT01143974 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Locally Advanced Malignant Neoplasm
|
June 2010 | Phase 4 |
NCT03456063 | Hoffmann-La Roche |
Non-Small-Cell Lung
|
April 24, 2018 | Phase 3 |
NCT04380636 | Merck Sharp & Dohme LLC |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung
|
July 6, 2020 | Phase 3 |
NCT02604342 | Hoffmann-La Roche |
Non-small Cell Lung Cancer
|
November 3, 2015 | Phase 3 |
NCT01656551 | National Cancer Institute, Naples |
Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB
|
August 2012 | Phase 3 |
NCT01107626 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
August 12, 2010 | Phase 3 |
NCT01496742 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
April 2012 | Phase 2 |
NCT04042558 | Centre Francois Baclesse|GFPC |
NSCLC Stage IIIB|NSCLC Stage IV|EGFR Gene Mutation|ALK Gene Rearrangement Positive|ROS1 Gene Mutation
|
September 26, 2019 | Phase 2 |
NCT03228537 | National Cancer Institute (NCI) |
Biphasic Mesothelioma|Epithelioid Mesothelioma|Stage I Pleural Malignant Mesothelioma AJCC v7|Stage IA Pleural Malignant Mesothelioma AJCC v7|Stage IB Pleural Malignant Mesothelioma AJCC v7|Stage II Pleural Malignant Mesothelioma AJCC v7|Stage III Pleural Malignant Mesothelioma AJCC v7
|
November 3, 2017 | Phase 1 |
NCT00573989 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Head and Neck Cancer
|
March 2008 | Phase 1|Phase 2 |
NCT00573690 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 2007 | Phase 1 |
NCT00454194 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
September 2007 | Phase 2 |
NCT01443078 | Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|United States Department of Defense |
Lung Cancer
|
October 2011 | Phase 2 |
NCT03520686 | ImmunityBio, Inc. |
Non Small Cell Lung Cancer
|
May 18, 2018 | Phase 3 |
NCT00191503 | Eli Lilly and Company |
Adenocarcinoma
|
January 2005 | Phase 2 |
NCT01192165 | GlaxoSmithKline |
Cancer
|
September 14, 2010 | Phase 1 |
NCT00686959 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
September 2008 | Phase 3 |
NCT01185847 | Hoffmann-La Roche |
Non-Squamous Non-Small Cell Lung Cancer
|
November 2010 | Phase 2 |
NCT00895648 | University Health Network, Toronto|Eli Lilly and Company |
Mesothelioma|Pleural Mesothelioma
|
January 2009 | Phase 2 |
NCT00022646 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
August 2001 | Phase 2 |
NCT00517595 | Accelerated Community Oncology Research Network|Eli Lilly and Company|Genentech, Inc. |
Non-Small Cell Lung Cancer
|
August 2007 | Phase 2 |
NCT04768075 | Guangdong Association of Clinical Trials |
Non-Small-Cell Lung Cancer
|
March 5, 2021 | Phase 3 |
NCT05012254 | Fundación GECP |
Non Small Cell Lung Cancer|Brain Metastases, Adult|Lung Cancer
|
November 18, 2021 | Phase 2 |
NCT00227565 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
February 2006 | Phase 2 |
NCT01958372 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
August 2014 | Phase 1 |
NCT02794571 | Genentech, Inc. |
Advanced+Metastatic Tumors
|
May 23, 2016 | Phase 1 |
NCT03607149 | Centre Georges Francois Leclerc |
Non-small Cell Lung Cancer
|
April 6, 2017 | Phase 4 |
NCT03819465 | AstraZeneca |
Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
December 27, 2018 | Phase 1 |
NCT01860508 | Fudan University |
Non-small Cell Lung Cancer
|
February 2013 | Not Applicable |
NCT01017874 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
November 2009 | Phase 3 |
NCT04396457 | National Hospital Organization Nagoya Medical Center|Central Japan Lung Study Group|Merck Sharp & Dohme LLC |
Non-squamous Non-small-cell Lung Cancer|Cancer, Lung
|
May 25, 2020 | Phase 2 |
NCT00402051 | Eli Lilly and Company |
Non-Small-Cell Lung Cancer
|
November 2006 | Phase 2 |
NCT01169675 | Boehringer Ingelheim |
Neoplasms
|
July 2010 | Phase 1 |
NCT00226577 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Eli Lilly and Company |
Lung Cancer
|
February 2004 | Phase 2 |
NCT04107103 | AHS Cancer Control Alberta|Alberta Cancer Foundation |
SCCHN
|
March 19, 2020 | Phase 2 |
NCT04786964 | Checkpoint Therapeutics, Inc. |
Metastatic Non-squamous Non Small Cell Lung Cancer
|
December 8, 2021 | Phase 3 |
NCT00948675 | Eli Lilly and Company |
Advanced Non-Small Cell Lung Cancer
|
September 1, 2009 | Phase 3 |
NCT01714037 | Debiopharm International SA|Syneos Health |
Non-small Cell Lung Cancer
|
August 2012 | Phase 1 |
NCT04372927 | University of Washington|AstraZeneca |
Locally Advanced Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8
|
December 10, 2021 | Phase 2 |
NCT05048797 | AstraZeneca|Daiichi Sankyo, Inc. |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
October 28, 2021 | Phase 3 |
NCT01351415 | Hoffmann-La Roche |
Non-Squamous Non-Small Cell Lung Cancer
|
June 25, 2011 | Phase 3 |
NCT00251550 | Eli Lilly and Company |
Malignant Pleural Mesotherioma
|
October 2005 | Phase 1|Phase 2 |
NCT00606021 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
January 2008 | Phase 2 |
NCT00738582 | Morphotek |
Malignant Pleural Mesothelioma
|
December 31, 2008 | Phase 2 |
NCT02426658 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Stage IV Non-Small Cell Lung Cancer
|
May 2015 | Phase 2 |
NCT00063570 | Eli Lilly and Company |
Breast Cancer|Breast Neoplasms
|
July 2003 | Phase 2 |
NCT01296568 | Eli Lilly and Company |
Advanced Cancer
|
February 2011 | Phase 1 |
NCT00589667 | Memorial Sloan Kettering Cancer Center |
Head and Neck Cancer
|
September 2006 | Phase 2 |
NCT00190840 | Eli Lilly and Company |
Carcinoma, Non-Small Cell Lung
|
September 2003 | Phase 2 |
NCT00334594 | Swiss Group for Clinical Cancer Research |
Malignant Mesothelioma
|
November 14, 2005 | Phase 2 |
NCT00394147 | Fox Chase Cancer Center|Eli Lilly and Company |
Head and Neck Cancer
|
October 2006 | Phase 2 |
NCT00227019 | Heather Wakelee|Eli Lilly and Company|Genentech, Inc.|Stanford University |
Non-small Cell Lung Cancer (NSCLC)|Lung Cancer|Neoplasm Metastasis
|
March 2006 | Phase 2 |
NCT03110484 | Samsung Medical Center |
Biliary Tract Cancer
|
July 9, 2021 | Phase 2 |
NCT03317496 | Pfizer |
Non-small Cell Lung Cancer|Urothelial Cancer
|
December 21, 2017 | Phase 1|Phase 2 |
NCT04585490 | Maximilian Diehn|AstraZeneca|Stanford University |
Non Small Cell Lung Cancer|NSCLC, Stage III|Nsclc
|
August 25, 2021 | Phase 3 |
NCT00868192 | Washington University School of Medicine|Columbia University |
Ovarian Carcinoma|Primary Peritoneal Carcinoma
|
May 2008 | Phase 2 |
NCT00916630 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Eli Lilly and Company|Dana-Farber Cancer Institute |
Central Nervous System Lymphoma
|
January 2009 | Phase 1 |
NCT02964689 | Swiss Group for Clinical Cancer Research |
Advanced Non-small Cell Lung Cancer|KRAS Gene Mutation|Lung Cancer
|
April 12, 2017 | Phase 1 |
NCT00447421 | Eli Lilly and Company |
Small Cell Lung Cancer|Carcinoma, Small Cell|SCLC
|
February 2007 | Phase 1|Phase 2 |
NCT01160744 | Eli Lilly and Company |
Carcinoma, Non-Small-Cell Lung
|
September 2010 | Phase 2 |
NCT00447057 | Eli Lilly and Company |
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
|
March 2007 | Phase 2 |
NCT01215916 | Eli Lilly and Company |
Solid Tumors
|
February 2008 | Phase 1 |
NCT03656549 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Non Small Cell Lung Cancer|Mesothelioma
|
February 1, 2019 | Phase 2 |
NCT04422392 | Shanghai Pulmonary Hospital, Shanghai, China |
Non Small Cell Lung Cancer
|
July 13, 2020 | Phase 2 |
NCT01567384 | Emory University|OSI Pharmaceuticals |
Cancer|Neoplasms|Tumors
|
May 2012 | Phase 1 |
NCT00502567 | AstraZeneca |
Advanced Solid Tumor
|
January 2005 | Phase 1 |
NCT02119650 | Incyte Corporation |
NSCLC (Non-small Cell Lung Carcinoma)
|
February 11, 2014 | Phase 2 |
NCT00320073 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2006 | Phase 1 |
NCT00456261 | SCRI Development Innovations, LLC|Genentech, Inc.|Eli Lilly and Company |
Lung Cancer
|
March 2007 | Phase 2 |
NCT04166487 | Dana-Farber Cancer Institute|Inivata |
NSCLC Stage IV|Metastatic Non-Small Cell Lung Cancer
|
January 13, 2020 | Phase 2 |
NCT03950674 | Merck Sharp & Dohme LLC |
Non-Small-Cell Lung Carcinoma
|
February 22, 2016 | Phase 3 |
NCT00491075 | M.D. Anderson Cancer Center|Eli Lilly and Company |
Renal Cell Carcinoma
|
December 2005 | Phase 2 |
NCT00102219 | Eli Lilly and Company |
Breast Cancer
|
October 2004 | Phase 2 |
NCT01358968 | Eli Lilly and Company |
Cancer
|
June 2011 | Phase 1 |
NCT05507606 | Tianjin Medical University Cancer Institute and Hospital |
Non Small Cell Lung Cancer
|
August 1, 2021 | Phase 2 |
NCT00402883 | SCRI Development Innovations, LLC|Genentech, Inc.|Eli Lilly and Company |
Lung Cancer
|
November 2006 | Phase 2 |
NCT02079636 | Eli Lilly and Company|Merck Sharp & Dohme LLC |
Carcinoma, Non-small Cell Lung
|
March 28, 2014 | Phase 1 |
NCT01187615 | Bayer |
Small Cell Lung Carcinoma
|
August 2010 | Phase 1 |
NCT02200354 | Kobe City General Hospital |
Advanced Non-small Cell Lung Cancer
|
July 2014 | Phase 2 |
NCT00191308 | Eli Lilly and Company |
Non-Small Cell Lung Cancer|Carcinoma
|
May 2005 | Phase 2 |
NCT04287894 | The Netherlands Cancer Institute|AstraZeneca |
Stage III NSCLC
|
December 28, 2018 | Phase 1 |
NCT03050437 | Samsung Medical Center |
Carcinoma, Non-Small-Cell Lung
|
March 2013 | Phase 2 |
NCT01774578 | NewLink Genetics Corporation|Lumos Pharma |
Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent
|
February 2013 | Phase 2|Phase 3 |
NCT03802240 | Innovent Biologics (Suzhou) Co. Ltd. |
Non-Squamous Non-Small Cell Lung Cancer
|
July 11, 2019 | Phase 3 |
NCT04335292 | Mark Vincent|AstraZeneca|Lawson Health Research Institute |
Non-Small Cell Lung Cancer
|
January 6, 2021 | Phase 2 |
NCT01548144 | M.D. Anderson Cancer Center |
Advanced Cancers
|
April 2012 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
H 2 O : ≥ 100 mg/mL ( 212.15 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.1215 mL | 10.6074 mL | 21.2148 mL |
5 mM | 0.4243 mL | 2.1215 mL | 4.2430 mL |
10 mM | 0.2121 mL | 1.0607 mL | 2.1215 mL |
Add each solvent one by one: Saline
Solubility: 100 mg/mL (212.15 mM); Clear solution; Need ultrasonic
Add each solvent one by one: PBS
Solubility: 50 mg/mL (106.07 mM); Clear solution; Need ultrasonic
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.